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1. Introduction 
This report describes the results of a proficiency 
test defined as External Quality Assurance 
System (EQAS) 2012 for antimicrobial 
susceptibility testing (AST) of enterococci, 
staphylococci and Escherichia coli. The results 
discussed in this report were obtained by 
National Reference Laboratories for 
Antimicrobial Resistance (NRL-AR) in Member 
States (MS) and in affiliated non-Member 
States of the European Union. 
This is the 12th
This EQAS aims to: i) monitor the quality of 
AST results produced by NRL-AR, ii) identify 
laboratories which may need assistance to 
improve their performance in AST, and iii) 
determine possible topics for further research or 
elaboration. 
 EQAS organized by the National 
Food Institute at the Technical University of 
Denmark (DTU Food) since its appointment as 
European Union Reference Laboratory for 
Antimicrobial Resistance (EURL-AR) by the 
European Commission (EC) in 2006. The 
EURL-AR is accredited by DANAK as provider 
of proficiency testing (accreditation no. 516); 
working with zoonotic pathogens and indicator 
organisms as bacterial isolates (identification, 
serotyping and antimicrobial susceptibility 
testing). 
In reading this report, the following important 
considerations should be taken into account: 
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determinations for all test strains in two 
different occasions at DTU-FOOD. These 
results were then verified by the United States 
Food and Drug Administration (FDA), Centre for 
Veterinary Medicine. Finally, a fourth MIC 
determination was performed at DTU-FOOD 
after preparation of the agar stab culture for 
shipment to participants to confirm that the vials 
contained the correct strains with the expected 
MIC values. 
2) Evaluation is based on interpretations of 
AST values determined by the participants. This 
is in agreement with the method used by MS to 
report AST data to EFSA, and complies with 
“the main objective of this EQAS to assess and 
improve the comparability of surveillance and 
antimicrobial susceptibility data reported to 
EFSA by the different NRLs”, as stated in the 
protocol. 
3) Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant. Since methods 
used for MIC determination have limitations, it 
is not considered a mistake to obtain a one-fold 
dilution difference in the MIC of a specific 
antimicrobial when testing the same strains. 
However, if the expected MIC is close to the 
breakpoint value for categorizing the strain as 
susceptible or resistant, a one-fold dilution 
difference, which is acceptable, may result in 
two different interpretations, i.e. the same strain 
will be categorized as susceptible and resistant, 
which will be evaluated as correct in one case 
and incorrect in the other if the evaluation is 
based on interpretation of MIC values. Since 
this report evaluates the interpretations of AST 
values, some participants may find their results 
classified as wrong even though the actual MIC 
they reported is only one-fold dilution different 
from the expected MIC. In these cases, the 
participants should be confident about the good 
quality of their performance of AST. In the 
organization of the EQAS we try to avoid these 
situations by choosing test strains with MIC 
values distant from the breakpoints for 
resistance, which is not always feasible for all 
strains and all antimicrobials. Therefore, the 
EURL-AR network unanimously established in 
2008 that if there are less than 75 % correct 
results for a specific strain/antimicrobial 
                                                             
 
4 
combination, the reasons for this situation must 
be further examined and, on selected occasions 
explained in details case by case, these results 
may subsequently be subtracted from the 
evaluation report. 
4) The EURL-AR network agreed on setting the 
accepted deviation level for laboratory 
performance to 5 %. 
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRLs who 
meet once a year at the EURL-AR workshop. 
All conclusions presented in this report are 
publicly available. However, participating 
laboratories are identified by codes and each 
code is known only by the corresponding 
laboratory. The full list of laboratory codes is 
confidential information known only by relevant 
representatives of the EURL-AR and the EU 
Commission. 
2. Materials and Methods  
2.1 Participants in EQAS 2012 
In March 2012, a pre-notification to announce 
the EQAS 2012 on antimicrobial susceptibility 
testing of enterococci, staphylococci and E. coli 
was sent by e-mail to the 32 European NRLs 
for antimicrobial resistance designated by the 
MS (App. 1). Nine additional laboratories (one 
from each of the following countries: Croatia, 
Iceland, Norway, Romania, Serbia, Spain, 
Switzerland, The Netherlands and Turkey) were 
invited to take part in the EQAS 2012 on the 
basis of their participation in previous EQAS 
iterations and/or affiliation to the EU. 
Participants represented all EU countries 
except Luxembourg (App. 2). Among the 
Figure 1  European map showing the countries participating in EQAS 2012 
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designated NRLs, 25 submitted results for the 
enterococci strains, 29 submitted results for the 
staphylococci and 29 for the E. coli strains. The 
level of participation was similar to EQAS 2011 
in which 24, 29 and 29 laboratories submitted 
results for enterococci, staphylococci and E. 
coli, respectively. In addition, this report 
includes results from one laboratory for each of 
the following EU-affiliated country non-MS: 
Croatia, Norway, Serbia, Switzerland and 
Turkey (Figure 1). 
In total, this report includes AST results of 
enterococci strains submitted by 29 
laboratories, and AST results of staphylococci 
strains submitted by 34 laboratories and E. coli 
strains submitted by 33 laboratories. 
2.2 Strains  
Bacterial strains included in this EQAS (eight 
enterococci, eight staphylococci and eight E. 
coli) were selected among the DTU-Food strain 
collection on the basis of antimicrobial 
resistance profiles and MIC values. For quality 
assurance purposes, one strain per each 
bacterial species tested has been included in all 
EQAS iterations performed to date, which 
represents an internal control. 
Antimicrobial susceptibility testing of the EQAS 
strains was performed at DTU-Food by MIC 
determination using the Sensititre system from 
Trek Diagnostic Systems. The MIC values 
obtained (App. 3) were used as reference 
values for this EQAS trial after verification 
performed by the U.S. FDA. After comparison 
and verification of the MIC values obtained at 
DTU-Food and FDA, the strains were 
inoculated in agar as stab cultures and 
dispatched to the participating laboratories. 
Reference strains E. faecalis ATCC 29212, S. 
aureus ATCC 25923, S. aureus ATCC 29213 
and E. coli ATCC 25922 were provided to new 
participating laboratories with instructions to 
store and maintain them for quality assurance 
purposes and future EQAS trials. 
2.3 Antimicrobials  
The panels of antimicrobials recommended for 
AST are listed in Table 1. 
Guidelines for performing AST were set 
according to the Clinical and Laboratory 
Standards Institute (CLSI) document – M7-A9 
(2012) “Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow 
Aerobically; Approved Standard - Ninth Edition”. 
MIC results were interpreted by using EUCAST 
epidemiological cut-off values 
(www.eucast.org), as recommended by EFSA 
and described in the protocol (App. 4). Results 
of ESBL detection tests were interpreted 
according to the recommendations reported in 
the EUCAST expert rules.  
All the above-mentioned choices were made on 
the basis of agreements reached by NRL 
participants at EURL-AR workshops in previous 
years. 
2.4 Distribution  
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu), thereby EQAS 
participants could access necessary information 
at any time. In June 2012, bacterial strains in 
agar stab cultures were dispatched in double 
pack containers (class UN 6.2) to the 
participating laboratories according to the 
International Air Transport Association (IATA) 
regulations as UN3373, biological substances 
category B. 
2.5 Procedure 
Participants were instructed to keep the agar 
stab cultures refrigerated until performance of 
antimicrobial susceptibility tests (App. 4). In 
addition, instructions for interpretation of 
antimicrobial susceptibility test results were 
provided. For interpretation of MIC 
determination results, cut-off values were 
reported in the protocol (App. 4: Tables 1, 2 and 
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3). For interpretation of disk-diffusion (DD) 
method results, participants were advised to 
use interpretive breakpoints as in their routine 
methods (App. 5). In both cases, the EQAS test 
strains should have been categorized as 
resistant or susceptible, and the EURL-AR 
recommended interpreting intermediate results 
as susceptible. 
Of note, the terms ‘susceptible’, ‘intermediate’ 
and ‘resistant’ should be reserved to categorize 
strains in relation to the therapeutic application 
of antimicrobial agents, while interpretation of 
AST results based on epidemiological cut-off 
values should result in categorization of 
bacterial strains in ‘wild-type’ or ‘non-wild-type’. 
However, due to different AST methods used by 
the participants and to simplify the interpretation 
of results, we will use the terms susceptible and 
resistant throughout this report even in the 
cases in which we refer to wild-type and non-
wild-type strains.  
All participating laboratories were invited to 
enter the obtained results into an electronic 
record sheet at the EURL-AR web-based 
database through a secured individual login and 
password. Alternatively, it was offered the 
possibility to fill-in a record sheet (provided with 
the protocol) and send it to the EURL-AR by 
fax, mail or email. 
The record sheet contained also space for 
reporting the results (zone diameters in 
millimeters or MIC values in μg/ml) obtained for 
the reference strains. These results were 
compared to the quality control ranges reported 
by CLSI in documents M31-A3 (2008) / M100-
S22 (2012) (App. 6).  
The website was inaccessible from the 10th of 
September to the 8th of October due to issues 
related to an upgrading. The database was 
finally closed and evaluations were made 
available to participants on the 8th of October 
2012. 
After this date, the participants were invited to 
login again to retrieve a database-generated 
individual report which contained an evaluation 
of the submitted results including possible 
deviations from the expected interpretations. 
Finally, participants were encouraged to 
Table 1. Panel of antimicrobials recommended for susceptibility testing of bacteria included in this EQAS 2012 
component 
Enterococci trial Staphylococci trial* Escherichia coli trial 
Ampicillin† Cefoxitin Ampicillin† 
Chloramphenicol† Chloramphenicol  Cefotaxime† 
Ciprofloxacin  Ciprofloxacin Cefoxitin 
Erythromycin† Erythromycin Ceftazidime 
Gentamicin† Florfenicol Ceftiofur 
Linezolid† Gentamicin Chloramphenicol† 
Streptomycin† Penicillin Ciprofloxacin† 
Quinupristin-dalfopristin† Streptomycin Florfenicol 
Tetracycline† Sulphonamides Gentamicin† 
Vancomycin† Tetracycline Nalidixic acid† 
 Trimethoprim Streptomycin† 
  Sulphonamides† 
  Tetracycline† 
  Trimethoprim† 
†Antimicrobials recommended by EFSA for monitoring antimicrobial resistance in Europe  
*No specific recommendations have been suggested by EFSA for monitoring resistance in staphylococci 
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complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials 
3. Results 
3.1 EQAS 2012 compared to 
previous EQAS iterations 
In EQAS 2012, the overall percentages of 
deviations from expected results were 4.6 %, 
2.0 % and 1.6 % for enterococci, staphylococci 
and E. coli, respectively (Figure 2). These 
percentages were slightly lower for enterococci, 
the staphylococci and E. coli trials when 
compared to the ones observed in 2011. The 
internal control strains (ENT-6.2, ST-6.8 and 
EC-6.4) followed the same decreasing pattern 
with 5.0 %, 1.4 % and 0.5 % deviating from the 
expected values. (Figure 2). Of note, these 
percentages do not include specific 
combinations strain/antimicrobial for which we 
observed less than 75 % reported results in 
agreement with the expected results (detailed 
explanation is provided in the paragraphs 
below).  
3.2 Deviations from expected 
results divided by species tested 
and AST method used 
In the data analysis, results were grouped 
according to the methods used by the 
participants as follows. The agar dilution 
method and MIC determination were evaluated 
together as they are both quantitative methods 
giving results corresponding to the minimum 
concentration of an antimicrobial which inhibits 
growth of the bacterial strain tested. The 
ROSCO and DD methods were evaluated 
together since they are based on the same 
principle of antimicrobial diffusion in the agar. 
Figure 2 Overview of the percentages of deviations from expected results obtained in different EQAS 
iterations for the three bacterial species tested. The internal control strain is represented by a line. 
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Higher percentages of deviations from expected 
results were obtained by performing AST by DD 
methods as compared to MIC determinations 
(Figure 3), as observed in previous EQAS 
iterations. Indeed, the percentage of deviations 
from expected results was 10 times higher for 
results obtained by DD compared to MIC in the 
enterococci trial. 
In EQAS 2012, 25, 26 and 29 participants 
performed AST by MIC determination for 
enterococci, staphylococci and E. coli, 
respectively, and four, eight and four 
participants performed AST by DD for 
enterococci, staphylococci and E. coli, 
respectively. 
Overall, the percentage of results in agreement 
with the expected values ranged from a 
minimum of 93.8 % (strain ENT 6.1) to a 
maximum of 99.5 % (strains EC 6.4), as shown 
in Table 2. The E. coli trial resulted in the 
highest percentages of results in agreement 
with the expected values. 
Detailed analysis of the results obtained for 
each species and strain tested in EQAS 2012 
are reported in the following paragraphs. 
3.2.1 Enterococci trial 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
individually examined and possibly subtracted 
from the general analysis if there are less than 
75 % correct results for a strain/antimicrobial 
combination in the ring trial.  
No results were omitted from the enterococci 
trial, as the combination with lowest percent 
age of correct results ENT-6.1-erythromycin 
resulted in a percentage of 76 % correct results 
and was therefore included in the report. 
Analysis of results deviating from expected 
Table 2. Total number of antimicrobial susceptibility tests (AST) performed for each EQAS 2012 strain and percentage 
(%) of correct results 
Strain* No. AST 
No 
correct 
% 
correct Strain* 
No. 
AST 
No 
correct 
% 
correct Strain* 
No. 
AST 
No 
correct 
% 
correct 
ENT-6.1 259 243 93,8% ST-6.1 287 283 98.6% EC 6.1 383 375 97.9% 
ENT-6.2 259 246 95,0% ST-6.2 319 305 95.6% EC 6.2 383 371 96.9% 
ENT-6.3 247 236 95,5% ST-6.3 319 309 96.9% EC 6.3 383 379 99.0% 
ENT-6.4 245 232 94,7% ST-6.4 318 315 99.1% EC 6.4 383 381 99.5% 
ENT-6.5 245 233 95,1% ST-6.5 320 316 98.8% EC 6.5 383 380 99.2% 
ENT-6.6 245 238 97,1% ST-6.6 320 316 98.8% EC 6.6 383 376 98.2% 
ENT-6.7 245 234 95,5% ST-6.7 319 313 98.1% EC 6.7 350 345 98.6% 
ENT-6.8 244 234 95,9% ST-6.8 287 283 98.6% EC 6.8 384 376 97.9% 
*ENT, enterococci; ST, staphylococci; EC, Escherichia coli. 
Figure 3 EQAS 2012: results deviating from the 
expected interpretation subdivided by tested species 
and antimicrobial susceptibility test method used. 
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interpretation subdivided by strain showed that 
percentage of deviations from expected results 
ranged from 2.9 % (ENT 6.6) to 6.2 % (ENT 
6.1) (Figure 4). The lowest percentage of 
deviation (2.9 %) was observed for ENT 6.6 
(Figure 4). Laboratories performing AST by DD 
reported results highly deviating from the 
expected categories ranging from 13.9 % (for 
ENT-6.3) to 27.8 % (for ENT-6.4), as shown in 
Figure 4. Out of 29 laboratories participating in 
the enterococci trial, only four performed AST 
by DD. 
Analysis of the results according to the tested 
antimicrobials showed that the highest 
percentages of deviation from expected 
interpretations were obtained in testing 
susceptibility to streptomycin (9.8 %), 
gentamicin and erythromycin (5.2 % for both) 
(Figure 5). Of note, streptomycin, gentamicin 
and erythromycin are among the EFSA-
recommended antimicrobials (Table 1). An 
overview of obtained and expected results is 
reported in Appendix 7a. 
3.2.2 Staphylococci trial 
Analysis of the different strain/antimicrobial 
combinations showed that ST-6.1/ciprofloxacin 
Figure 4 Enterococci trial: results deviating from the expected interpretation subdivided by tested strain and 
antimicrobial susceptibility test method used  
 
 
Figure 5. Enterococci trial: results deviating from expected interpretation according to the tested 
antimicrobials. 
 
*Antimicrobials recommended by EFSA for antimicrobial resistance monitoring within EU 
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and ST6.8/ciprofloxacin were categorized in 
agreement with the expected category by only 
57.1% and 34.5% of the participants, 
respectively. According to the decision 
established by the EURL-AR network, further 
analysis was performed to examine the reason 
of these unsatisfactory results.  
The expected MIC of ST 6.1 was 1 μg/ml, which 
results in categorization of the strain as 
susceptible. However, this value is one-step 
dilution just below the cut-off value (please refer 
to protocol, App. 4). Participants obtaining a 
MIC of 2 μg/ml, which is acceptable as it is 
within one-fold dilution difference from the 
expected value, categorized the strain as 
resistant and this was evaluated as an error. 
Fourteen participants obtained an MIC of 0.5-1 
and classified the strain as susceptible, while 
thirteen participants obtained an MIC of >1 to 4 
μg/ml and classified it incorrectly as resistant. 
Among the seven participants performing DD, 
two erroneously categorized the strain as 
resistant. All these results have been subtracted 
from the main analysis reported in this 
evaluation report since they cannot be 
representative of the quality of performance of 
the different participants in AST. 
Regarding ST6.8/ciprofloxacin, the results were 
analyzed in a similar way. The expected MIC for 
this strain/antimicrobial combination was 2 
µg/ml and the strain was expected to be 
classified as resistant. However, this value is 
one-step dilution above the cut-off value 
(please refer to protocol, App. 4) and 
participants obtaining an MIC of 1 μg/ml, which 
is acceptable as it is within one-fold dilution 
difference from the expected value, categorized 
the strain as susceptible and this was evaluated 
as an error. Thirteen participants obtained an 
MIC of 0.25-1 μg/ml and classified the strain 
incorrectly as susceptible, while only nine 
participants obtained an MIC of >1 to 4 μg/ml 
and classified it correctly as resistant. Among 
the seven participants performing DD, six 
erroneously categorized the strain as 
susceptible and only one assigned it correctly 
as resistant.  
All the results from both of these 
strain/antimicrobial combinations (ST 
6.1/ciprofloxacin and ST6.8/ciprofloxacin) have 
been subtracted from the main analysis 
reported in this evaluation report.  
Analysis of results deviating from expected 
interpretation subdivided by strain showed that 
percentage of deviations from expected results 
ranged from 0,9 % to 4,4 % (Figure 6). The 
highest percentage (4.4 %) of disagreement 
with expected results was obtained for ST-6.2 
(Figure 6). Percentage of disagreement with 
expected results was 0.9 % for strain ST 6.4 
(Figure 6). Laboratories performing AST by DD 
obtained results deviating from the expected 
categories in percentages comparable to the 
ones obtained by MIC determination, as shown 
in Figure 7. Out of 34 laboratories participating 
in the staphylococci trial, eight performed AST 
by DD. 
Analysis of the results according to the tested 
antimicrobials showed that the highest 
percentages of deviation from expected 
interpretations were obtained in testing 
susceptibility to sulfametoxazole (6.4 %), 
streptomycin (4.8 %) and trimethoprim (4.7 %) 
(Figure 7). Gentamicin resulted in a deviation 
percentage of 2.7 % and tetracycline 1.1 % 
while the remaining antimicrobials lead to less 
than 1.0 % of the results deviating from the 
expected (Figure 7). 
An overview of obtained and expected results is 
reported in Appendix 7b.  
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Strains ST6.1, ST6.6, ST6.7 and ST6.8 were 
methicillin-resistant. Among 34 participants 
testing staphylococci strains, one (lab # 57) did 
not report results concerning methicillin 
resistance. 
Methicillin-resistant strains 
One participant (lab #4) failed in detecting 
methicillin resistance in strain ST6.1. 
All remaining results were correct. 
 
 
3.2.3 Escherichia coli trial 
Analysis of the different strain/antimicrobial 
combinations showed that EC6.7/streptomycin 
was categorized in agreement with the 
expected category by only 70 % of the 
participants. According to the decision 
established by the EURL-AR network, further 
analysis was performed to examine the reason 
of this unsatisfactory result.  
The expected MIC was 16 μg/ml, which in 
categorized the strain as resistant. However, 
Figure 6 Staphylococci trial: results deviating from the expected interpretation subdivided by tested strain 
and antimicrobial susceptibility test method used  
 
 
Figure 7. Staphylococci trial: results deviating from the expected interpretation according to tested 
antimicrobial. 
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this value is one-step dilution above of the cut-
off value (please refer to protocol, App. 4) and 
participants obtaining a MIC of 8 μg/ml, which is 
acceptable as it is within one-fold dilution 
difference from the expected value, categorized 
the strain as susceptible and this was evaluated 
as an error. Six participants obtained a MIC of 8 
μg/ml and two participants obtained a MIC of 
≤16 μg/ml, fourteen participants obtained an 
MIC of 16 μg/ml (one of these classified as 
susceptible). The isolate exhibits resistance 
(borderline) to this drug. From the three 
participating laboratories performing DD, one 
erroneously categorized the strain as 
susceptible. All these results have been 
subtracted from the main analysis reported. 
Analysis of results deviating from expected 
interpretation subdivided by strain showed that 
percentage of deviations from all expected 
results ranged from 0.5 % to 3,1 % (Figure 8). 
The highest percentage (3.1 %) of 
disagreement with expected results was 
obtained for EC6.2 (Figure 8). Laboratories 
performing AST by DD obtained results 
deviating from the expected categories in 
percentages higher than the ones obtained by 
MIC determination, as shown in Figure 8. The 
results obtained by DD varied from 2.6 %- 10.5 
% which corresponds to three to 18 times 
higher percentages of deviations in AST 
performed by DD compared to MIC (Figure 8). 
Out of 33 laboratories participating in the E. coli 
Figure 8 Escherichia coli trial: results deviating from the expected interpretation subdivided by tested strain 
and antimicrobial susceptibility test method used 
 
 
Figure 9. Escherichia coli trial: results deviating from expected interpretation according to the tested 
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trial, four performed AST by DD. 
An overview of obtained and expected results is 
reported in Appendix 7c. 
Analysis of the results according to the tested 
antimicrobials showed that the highest 
percentages of deviation from expected 
interpretations were obtained in testing 
susceptibility to streptomycin (5.8 %), (Figure 
9). ceftazidime (3.7%) and ceftiofur (3.5%), 
gentamicin (2.7 %) and sulfametoxazole (2.1 
%), while tests of susceptibility to the remaining 
antimicrobials resulted in less than 2.0 % 
results deviating from the expected (Figure 9). 
No deviations were observed for 
chloramphenicol, florfenicol and trimethoprim 
susceptibility testing (Figure 9). 
An overview of obtained and expected results is 
reported in Appendix 7c. 
As described in the EQAS-protocol, MIC values 
and related interpretations for cefotaxime, 
ceftazidime and ceftiofur should be reported as 
found according to EUCAST expert rules. 
Cefotaxime susceptibility testing was performed 
98,9 % correctly by the participants who tested 
this antimicrobial, while 3.5 % and 3.7 % of 
results were in disagreement with the expected 
values for ceftiofur and ceftazidime, 
respectively. 
Beta-lactamase-producing E. coli 
Confirmation of beta-lactamase production is a 
mandatory component of this EQAS. All E. coli 
strains resistant to cefotaxime, ceftazidime 
and/or ceftiofur should undergo confirmatory 
tests for beta-lactamase production. Participant 
# 57 did not perform this component. 
EC6.4 and EC6.7 were extended-spectrum 
beta-lactamase (ESBL) producers and EC6.1 
and EC6.8 were AmpC-producers. 
Deviations from expected results were obtained 
as follows. 
Two participants (lab #54 and lab #57) did not 
identify EC6.4 and two participants (lab #39 and 
#54) and did not identify EC6.7 as ESBL 
producers as they did not obtained signs of 
synergy (please refer to protocol, App.4) by 
testing cefotaxime and cefotaxime+clavulanic 
acid. 
Participants #39, #54 and #57 did not identify 
both EC6.1 and EC6.8 as AmpC producers. 
Overall, these participants performed correct 
procedures except for the fact that the 
participant # 57 did not test for cefoxitin 
resistance and labs #39 and #54 did not 
classify the strain as AmpC despite finding they 
were resistant to cefoxitin and not showing 
synergi and finding the resistance to cefotaxime 
and ceftazidime in the AST panel whereas lab 
#57 did not perform confirmation of either ESBL 
or AmpC production.  
One of the participants(lab # 22) identified both 
EC6.1 and EC6.8 as AmpC producer and ESBL 
producers since they observed synergi in the 
test with ceftazidime and cefotaxime+clavulanic 
acid, for both strains and for cefotaxime and 
clavulanic acid for strain EC6.8 since an 
increase of the inhibition zone diameter ≥ 5 mm 
was observed. Furthermore they observed a 
reduced diameter zone for cefoxitin and 
therefore classified the strains also as AmpC 
producers, which is correct. 
Finally, one participant (lab # 39) classified EC-
6.3 erroneously as ESBL producer. In this case, 
participant # 39 categorized the strain as 
cefotaxime and ceftazidime resistant, 
performed confirmatory test and found synergy 
by testing cefotaxime and 
cefotaxime+clavulanic acid. 
3.3 Deviations from expected 
results analyzed by participating 
laboratory 
3.3.1 Enterococci trial 
Analysis of laboratory performance of AST 
restricted to EFSA-recommended antimicrobials 
showed that three out of 29 participants 
                                                             
 
14 
obtained a percentage of deviations from 
expected results higher than 5 % (Figure 10). 
Also by including all antimicrobials tested, the 
same participants obtained a percentage of 
deviations from expected results higher than 5 
%.  
Participant #54 obtained the largest number of 
deviations (72 % when considering all 
antimicrobials and 68.8% when considering the 
EFSA antimicrobials. These deviations from 
expected results were obtained by testing all 
reported antimicrobials and were all due to 
reporting as resistant strain/antimicrobial 
combinations which should have considered as 
susceptible. This was probably due to the DD 
method used, which lead to reduced diameter 
zones observed. 
Participant # 40 obtained 13.5% deviations from 
expected results mainly in testing gentamicin, 
quinupristin-dalfopristin and streptomycin 
(susceptible strains classified as resistant). 
Participant #34 reported 4 deviations including 
two for erythromycin (susceptible strains 
reported as resistant) and two for streptomycin 
(deviations observed in both directions 
regarding two strains). 
For further information please consult the 
overview in the Appendixes (App. 8a). 
In summary, 26 of 29 participants in the 
Figure 10. Percentage of deviations from expected results obtained by each laboratory in the enterococci trial. The 
laboratories were ranked by decreasing percentage of deviations from expected results in antimicrobial susceptibility 
testing including EFSA-recommended antimicrobials only. 
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enterococci trial achieved the acceptance level 
by having less than 5 % of results deviating 
from the expected values (Figure 10). Among 
the three participants who did not meet the 
acceptance level, one was considered an 
outlier (lab # 54) (Figure 11). 
Deviations from expected results obtained by 
each participant in the enterococci trial are 
reported in Appendix 8a. 
3.3.2 Staphylococci trial 
Analysis of laboratory performance of AST 
showed that three out of 34 participants 
obtained a percentage of deviations from 
expected results higher than 5.0 % (Figure 12). 
One out of seven participants performing AST 
by DD obtained more than 5.0 % deviations 
from expected results (Figure 12). 
Participant #54 obtained deviations from 
expected results mainly in testing gentamicin, 
streptomycin and ciprofloxacin (susceptible 
strains classified as resistant).  
Participant #20 obtained deviations from 
expected results mainly in testing 
sulfametoxazole, and trimethoprim (susceptible 
strains classified as resistant). Participant #58 
obtained deviations from expected results for 
sulfametoxazole, tetracycline and trimethoprim 
and both classification of susceptible strains as 
resistant and vice versa were observed (App. 
8b). 
In summary, 31 of 34 participants in the 
staphylococci trial achieved the acceptance 
level by having less than 5.0 % of results 
deviating from the expected values (Figure 12). 
One outlier (# 54) was identified among the 
three participants who did not meet the 
acceptance level (Figure 13). However, the 
Figure 12. Percentage of deviations from expected results obtained by each laboratory in the staphylococci 
trial. The laboratories were ranked by decreasing percentage of deviations from expected results in 
antimicrobial susceptibility testing 
 
*Laboratories performing AST by disc diffusion 
Figure 13. Number of laboratories categorized according to the percentage of deviations from expected results 
obtained by testing staphylococci strains for antimicrobial susceptibility  
 
 
0% 
5% 
10% 
15% 
20% 
54* 20 58 40 6 57* 13* 36 42 34 17 56* 39 4 18* 26 1 2 9 11 12 14* 15* 19 21 22 23 25 29 30 31 33 37 46 P
er
ce
nt
ag
e 
of
  d
ev
ia
tio
ns
 
Laboratory ID number 
                                                             
 
16 
participant (# 57) who did not report any 
information concerning methicillin resistance 
will been contacted by the EURL-AR to agree 
on possible supportive actions.  
Deviations from expected results obtained by 
each participant in the staphylococci trial are 
reported in Appendix 8b. 
 
3.3.3 Escherichia coli trial 
Analysis of laboratory performance of AST 
restricted to EFSA-recommended antimicrobials 
showed that two out of 33 participants obtained 
a percentage of deviations from expected 
results higher than 5 % (Figure 14). By 
including all antimicrobials tested, three out of 
33 participants obtained a percentage of 
deviations from expected results higher than 5 
% (Figure 15). 
Participant # 54 obtained deviations from 
Figure 14 Percentage of deviations from expected results obtained by each laboratory in the Escherichia coli 
trial. The laboratories were ranked by decreasing percentage of deviations from expected results in 
antimicrobial susceptibility testing 
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Figure 15. Number of laboratories categorized according to the percentage of deviations from expected results 
obtained by testing Escherichia coli strains for susceptibility to EFSA-recommended antimicrobials 
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expected results mainly in testing gentamicin, 
tetracycline and ampicillin (susceptible strains 
classified as resistant). Participant # 39 
obtained deviations from expected results for 
different antimicrobials including cefotaxime, 
ampicillin, and sulfametoxazole (susceptible 
strains classified as resistant). In the remaining 
case, deviations from expected results were 
observed for different antimicrobials and were 
represented both by classification of susceptible 
strains as resistant and vice-versa (App. 8c).In 
summary, 31 of 33 participants in the E. coli trial 
achieved the acceptance level by having less 
than 5 % of results deviating from the expected 
values when taking in account the EFSA 
recommended antimicrobials (Figure 14). 
Among the two participants who did not meet 
the acceptance level, both were considered 
outliers (Figure 15). One additional participant 
(# 57) reported results showing a percentage of 
deviations of 6.9 % when considering all 
antimicrobials, but had less than 5.0 % when 
considering only the EFSA recommended 
antimicrobials. Deviations from expected results 
obtained by each participant in the E. coli trial 
are reported in Appendix 8c. 
3.4 Deviations from expected 
results for the reference strains 
The results for antimicrobial susceptibility 
testing of the reference strains have been 
evaluated according to the CLSI-established 
quality control (QC) ranges (App. 6). 
3.4.1 Enterococcus faecalis ATCC 29212 
Twenty-four participants performed AST of E. 
faecalis ATCC 29212 by MIC determination. No 
results were found outside of range. In 
summary, out of 188 tests performed all were 
correct (Table 3). 
As CLSI has not published a QC range for E. 
faecalis ATCC 29212 using DD, the two 
laboratories (# 26 and # 57) that have entered 
data for the reference strain performing this 
method for AST could not be evaluated. 
3.4.2a Staphylococcus aureus ATCC 25923 
Six participants performed AST of S. aureus 
ATCC 25923 by DD (6). Two results outside of 
the QC range were obtained for cefoxitin, and 
tetracycline susceptibility tests and one result 
outside the QC range was obtained for 
gentamicin and penicillin susceptibility tests 
(Table 4). Per laboratory, the results show that 
one participant had four deviations (# 14) by 
measuring slightly larger diameter of the 
inhibition zones for cefoxitin, gentamicin, 
penicillin and tetracycline than the QC range. 
One laboratory (# 15) had a measurement of 
the inhibition zone for tetracycline above range 
and another (# 56) had a measurement of the 
inhibition zone for cefoxitin above range. In 
summary, out of 53 tests performed overall, 47 
were correct. 
One participant (# 4) performed AST of S. 
aureus ATCC 25923 by ROSCO method, and 
the results were not included in Table 4 
because the quality control values were 
different from the ones used for DD. This 
participant (lab #4) obtained one results outside 
the QC range for cefoxitin. 
3.4.2b Staphylococcus aureus ATCC 29213 
Twenty-five participants performed AST of S. 
aureus ATCC 29213 by MIC determination 
(Table 5). No deviation was obtained. In 
summary, out of 207 tests performed, all were 
correct. 
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3.4.3 Escherichia coli ATCC 25922 
Three participants performed AST of E. coli 
ATCC 25922 by DD. One of these laboratories 
had all results correct # 15, whereas the other 
laboratories # 14 and # 57, had two and four 
results outside of the QC range, respectively. 
The six deviations observed were one deviation 
each on the results for cefotaxime, ceftiofur, 
chloramphenicol, ciprofloxacin, sulfisoxazole 
and tetracycline (Table 6). In summary, out of 
31 tests performed overall, 25 were correct. 
Twenty-eight participants performed AST of E. 
coli ATCC 25922 by MIC determination. Sixteen 
deviations were observed including five 
deviations for the results for ciprofloxacin, three 
for gentamicin, and one deviation each for 
imipenem, nalidixic acid, sulfixazole and 
tetracycline (Table 7). Regarding the distribution 
per laboratories one laboratory (lab #40) 
reported seven results outside the range for the 
QC strain. This was probably due to a switch of 
the QC strain. Then, three laboratories (lab #4, 
and #36) reported two results out of range, 
three laboratories (labs #11, #23 and #33) 
reported one result out of range for this QC 
strain and the remaining did not have any 
deviations on the QC strain. In summary, out of 
312 tests performed, 296 were correct. 
Table 3. Antimicrobial susceptibility testing of Enterococcus faecalis ATCC 29212 by MIC determination: deviations from 
expected values and minimum and maximum values reported for each tested antimicrobial 
Enterococcus faecalis ATCC 29212 
Antimicrobial QC range (MIC) Min. value Max. value No. of deviations from expected result/ Total no. of tests 
Ampicillin  0.5 - 2 0.5 2 0/19 
Chloramphenicol 4-16 4 16 0/24 
Ciprofloxacin  0.25 - 2 0.25 1 0/19 
Erythromycin 1 - 4 1 4 0/24 
Gentamicin 4 - 16 4 <=128 0/22 
Linezolid 1 - 4 1 2 0/20 
Quinu-dalfo-pristin  2 - 8 2 8 0/12 
Streptomycin  n.a.* 16 1000 0/18 
Tetracycline 8 - 32 8 32 0/24 
Vancomycin 1 - 4 1 4 0/24 
*n.a., not applicable 
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Table 4. Antimicrobial susceptibility testing of Staphylococcus aureus ATCC 25923 by disk diffusion: deviations from 
expected values and minimum and maximum values reported for each tested antimicrobial 
Staphylococcus aureus ATCC 25923 
Antimicrobial QC range (DD) Min. value Max. value 
No. of deviations from expected 
result/Total no. of tests 
Cefoxitin 23 – 29 26 32 2/6 
Chloramphenicol 19 – 26 23 26 0/5 
Ciprofloxacin 22 – 30 24 29 0/5 
Erythromycin 22 – 30 25 30 0/6 
Florfenicol n. a. 24 27 0/3 
Gentamicin 19 – 27 22 30 1/6 
Penicillin 26 – 37 32 40 1/6 
Streptomycin 14 – 22 15 22 0/3 
Sulfisoxazole 24 – 34 24 30 0/4 
Tetracycline 24 – 30 27 31 2/6 
Trimethoprim 19 - 26 20 26 0/3 
 
Table 5. Antimicrobial susceptibility testing of Staphylococcus aureus ATCC 29213 by MIC determination: deviations 
from expected values and minimum and maximum values reported for each tested antimicrobial 
Staphylococcus aureus ATCC 29213 
Antimicrobial QC range (MIC) Min. value Max. value 
No. of deviations from expected 
result/Total no. of tests 
Cefoxitin 1 - 4 2 4 0/19 
Chloramphenicol 2 - 16 2 16 0/24 
Ciprofloxacin 0.12 - 0.5 0.12 1 0/24 
Erythromycin 0.25 - 1 0.25 1 0/25 
Florfenicol 2 - 8 4 8 0/6 
Gentamicin 0.12 - 1 <=0.25 <=2 0/24 
Penicillin 0.25 - 2 0.25 2 0/25 
Sulfisoxazole 32 - 128 <=64 128 0/12 
Tetracycline 0.12 - 1 <=0.5 <=2 0/25 
Trimethoprim 1 - 4 1 4 0/23 
 
Table 6. Antimicrobial susceptibility testing of Escherichia coli ATCC 25922 by disk diffusion: deviations from expected 
values and minimum and maximum values reported for each tested antimicrobial 
Escherichia coli ATCC 25922 
Antimicrobial QC range (DD) Min. value Max. value 
No. of deviations from expected 
result/Total no. of tests 
Ampicillin 16 - 22 21 21 0/1 
Cefotaxime 29 - 35 32 36 1/3 
Cefoxitin 23 - 29 28 28 0/3 
Ceftazidime 25 - 32 26 32 0/3 
Ceftiofur 26 - 31 23 31 1/3 
Chloramphenicol 21 - 27 26 32 1/2 
Ciprofloxacin 30 - 40 25 37 1/2 
Gentamicin 19 - 26 23 26 0/3 
Imipenem 26 - 32 nt nt 0/0 
Nalidixic acid 22 - 28 25 28 0/3 
Streptomycin 12 - 20 19 20 0/2 
Sulfisoxazole 15 - 23 24 24 1/1 
Tetracycline 18 - 25 23 26 1/3 
Trimethoprim 21 - 28 25 27 0/2 
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4. Discussion 
4.1 General overview 
In the overall analysis of results, it could be 
observed that the levels of deviations from the 
expected results were comparable to last year 
for AST of staphylococci and enterococci, while 
there was a decrease in deviations from the 
expected results for AST of E. coli (Figure 2). 
The percentage of deviations from the expected 
results for AST of the internal control strains 
followed a trend towards a decrease in all 
species tested (Figure 2).  
It is important to consider that the number of 
EQAS participants changes from year to year, 
which implies that comparisons among different 
EQAS iterations are difficult to interpret. Results 
from five laboratories from EU–affiliated 
countries non-MS were included in this report, 
which is a larger number than compared to 
reports issued in previous years.  
The EURL-AR has emphasized the need for 
harmonization of AST methodology among 
NRLs, and has recommended MIC 
determination on several occasions. In this 
EQAS trial, the number of participants 
performing MIC determination is comparable to 
the high numbers observed last year. Of note, 
enterococci and E. coli AST performed by MIC 
determination resulted in significantly higher 
percentages of correct results compared to 
results obtained by DD over the different EQAS 
iterations.  
4.2 Enterococci trial 
The percentages of results deviating from the 
expected interpretations varied from circa 3 % 
to 6 % among the different test strains (Figure 
4). The relatively high percentages of deviations 
from expected results were mainly generated 
by participants performing AST by DD (Figure 
Table 7. Antimicrobial susceptibility testing of Escherichia coli ATCC 25922 by MIC determination: deviations from 
expected values and minimum and maximum values reported for each tested antimicrobial 
Escherichia coli ATCC 25922 
Antimicrobial QC range (MIC) Min. value Max. value 
No. of deviations from expected 
result/Total no. of tests 
Ampicillin 2 - 8 1 8 1/28 
Cefotaxime 0.03 - 0.125 ≤0,06 0,25 1/28 
Cefoxitin 2 - 8 ≤4 8 0/9 
Ceftazidime 0.06 - 0.5 ≤0,25 1 1/25 
Ceftiofur 0.25 - 1 0,25 1 0/4 
Chloramphenicol 2 - 8 2 16 1/28 
Ciprofloxacin 0.004 - 0.016 ≤0,008 0,06 5/28 
Gentamicin 0.25 - 1 0,5 4 3/28 
Imipenem 0.06 - 0.25 0,12 0,5 1/5 
Nalidixic acid 1 - 4 2 16 1/28 
Streptomycin 4 - 16 ≤4 16 0/27 
Sulfisoxazole 8 - 32 ≤8 256 1/19 
Tetracycline 0.5 - 2 ≤1 8 1/28 
Trimethoprim 0.5 - 2 ≤0,5 2 0/27 
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4).  
Similar problems were observed last year in 
EQAS 2011 and previously. Enterococci appear 
to be quite difficult to test correctly by DD, and 
several different reasons may be found. 
Unsatisfactory performance may be due to 
factors related to the strains as certain 
enterococci strains may require incubation 
times longer than overnight incubation. In 
addition, inoculum size and density may also 
represent a source of errors in AST 
performance. The outcome of AST by DD is 
also influenced by factors related to the agar 
media like humidity, pH and volume. Finally, 
there may be factors related to the 
antimicrobial-containing disks like expiry date, 
humidity and concentration used. In addition, 
CLSI does not provide a QC range for the 
testing of the reference strain by DD, which 
does not allow to validate the data obtained by 
using this method, in the same way as it can be 
performed using MIC testing. 
Susceptibility tests to streptomycin, 
erythromycin and gentamicin resulted in the 
highest percentages of results deviating from 
the expected interpretations (Figure 5).  
For streptomycin the incorrect classification was 
represented both by susceptible strains 
reported as resistant and vice versa, which was 
reported by various participants including #34, # 
40, # 41, # 54 and # 57 (App. 8a). Regarding 
gentamicin, the incorrect classification was 
represented by susceptible strains reported as 
resistant, which was mainly obtained by 
participants #40 and # 54 (App. 8a). For 
erythromycin, as mentioned before, several 
laboratories have classified strain 6.1 as 
resistant to erythromycin and further deviations 
in other strains were only obtained by two 
participants (# 34 and # 54) which classified 
some of the remaining susceptible strains as 
resistant. Of note, erythromycin, gentamicin and 
streptomycin are among the EFSA-
recommended antimicrobials, which implies that 
it is important that each participant who 
submitted incorrect results takes corrective 
actions. 
The number of participants submitting more 
than 5 % results deviating from the expected 
interpretation was three, which is three less 
than compared to last year (Figure 10). Of note, 
only one of these three participants performed 
testing by DD However, there was a greater 
number of deviations occurring when 
performing DD, when compared to MIC 
methods. 
Among the three participants who did not meet 
the 5.0 % acceptance threshold, one was 
considered an outlier with ca 72 % deviations, 
mainly due to susceptible strains classified as 
resistant for most antimicrobials. Another two 
participants reported ca 14 % and 6 % of 
results in disagreement with the expected 
values and was therefore considered as above 
the threshold but not considered as outliers 
(Figure 11). The three participants have been 
contacted by the EURL-AR to identify possible 
causes of this unsatisfactory performance and 
to improve the quality of results. 
The number of participants performing AST with 
100 % agreement with the expected results was 
8 (28 %), which is two laboratories less than 
last year.  
AST of the quality control strain E. faecalis 
ATCC 29212 was excellent for the 22 
participants that tested this strain by MIC 
determination (Table 3). In summary, out of 188 
tests performed overall, all (100%) were 
correct. Of note, the outlier (# 54) identified in 
the enterococci trial did report DD results for the 
quality control strain, which were therefore not 
evaluated and the other outlier (#40) reported 
MIC results for most antimicrobials, but not for 
quinupristin-dalfopristin, ampicillin and 
streptomycin. 
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4.3 Staphylococci trial 
The percentages of results deviating from the 
expected interpretations ranged from 1 % to 4 
% among the different test strains (Figure 6). 
The percentages of deviations from expected 
results generated by participants performing 
MIC determination and by participants 
performing DD were this time more 
differentiated, with better results being obtained 
by those performing MIC testing (Figure 7). The 
number of participants performing MIC 
determination increased from 25 (EQAS 2011) 
to 27 participants. 
The overall satisfactory results obtained in the 
staphylococci trial show a successful 
implementation of the new method for AST. 
Identification of methicillin-resistant strains was 
generally satisfactory, which demonstrated that 
laboratories within the EURL-AR network 
correctly identify MRSA. However, few 
improvements are necessary as participant # 
57 did not report results concerning methicillin 
resistance, and participant # 4 reported strain 
ST 6.1 as methicillin susceptible. 
The number of participants submitting more 
than 5 % results deviating from the expected 
interpretation was three (Figure 12), which is 
two more compared to last year. One outlier 
(#54) which obtained 17 % results deviating 
from expected values was identified in the 
staphylococci trial (Figure 13). The EURL-AR 
has contacted the three participants to identify 
possible causes of this unsatisfactory 
performance and to improve the quality of 
results. 
The number of participants performing AST with 
100 % agreement with the expected results was 
18 (53 %). 
AST of the quality control strain S. aureus 
ATCC 25923 (for DD) resulted in 89 % correct 
tests (Table 4), and AST of the quality control 
strain S. aureus ATCC 29213 (for MIC 
determination) resulted in 100 % correct tests 
(Table 5). Overall, this performance was quite 
satisfactory.  
4.4 Escherichia coli trial 
The percentages of results deviating from the 
expected interpretations varied from 0.5 % to 
3.1 % among the different test strains (Figure 
8). These relatively percentages of deviations 
from expected results were lower than in the 
previous year and mainly generated by 
participants performing AST by DD (Figure 8).  
Susceptibility tests to streptomycin resulted in 
the highest percentages (6.8 %) of results 
deviating from the expected interpretations 
(Figure 9), and were mostly due to 
interpretation of susceptible strains as resistant. 
For ceftazidime, the incorrect classification was 
both represented by susceptible strains 
reported as resistant and vice versa, which was 
an issue for several participants (App. 8c). For 
ceftiofur, the incorrect classification was 
represented only by two resistant strains 
reported as susceptible by one participant # 29 
(App. 8c). These results indicate that increased 
attention should be paid to correctly categorize 
strains according to susceptibility to critically 
important antimicrobials like ceftazidime and 
ceftiofur ( 3rd
The number of participants submitting more 
than 5 % results deviating from the expected 
interpretation regarding EFSA recommended 
antimicrobials was three, which is lower than 
last year when seven participants performed 
outside the acceptance level (Figure 14). One 
out of four participants testing E. coli by DD 
obtained percentages of results deviating from 
the expected interpretations above the 5 % 
threshold for acceptable AST performance. 
Among the three participants who did not meet 
the 5 % acceptance threshold, two were 
considered an outliers (Figure 15). All three 
laboratories reporting deviation levels above the 
threshold have been contacted by the EURL-
AR to identify possible causes of this 
unsatisfactory performance and to improve the 
 generation cephalosporins).  
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quality of results. 
The number of participants performing AST with 
100 % agreement with the expected results was 
26 (79 %). 
Detection of beta-lactamases of the ESBL and 
AmpC-type should be further improved 
especially concerning identification of AmpC-
type beta-lactamases. Participants did not show 
difficulties in correctly identifying cephalosporin 
resistance and a general improvement was 
observed compared to last year. However, there 
are limitations in the correct performance and 
interpretation of ESBL and AmpC confirmatory 
tests.  
AST of the quality control strain E. coli ATCC 
25922 resulted in 81 % and 95 % correct tests 
by DD and MIC determination, respectively 
(Tables 6 and 7). Overall, this performance was 
quite satisfactory. However, as for previous 
years the majority of deviations was observed 
for tests of ciprofloxacin and this results must 
be improved in future trials since ciprofloxacin is 
among the critically important antimicrobials as 
defined by the WHO. One of the participants 
mentioned above reporting more than 5 % 
incorrect results for specific antimicrobials (#39) 
had no deviations when testing the QC 
reference strain whereas the participant 
reporting the highest number of deviations in 
the E. coli trial (# 54) did not submit data for the 
reference strain testing. 
5. Conclusions 
The number of laboratories not performing AST 
within the acceptable level (i.e. > 5 % results 
deviating from the expected values) was 
relatively low. One participant was classified as 
an outlier both in the enterococci and in the 
staphylococci trial and two in the E. coli trial. 
Since one of the tasks of the EURL-AR is to 
give specific recommendations targeting 
individual difficulties in performing acceptable 
AST, laboratories outside the acceptable level 
have been contacted to assess the causes of 
inadequate AST performance and provide 
guideline to improve the methods used. These 
individual contacts should be taken as an 
opportunity to improve knowledge on AST.  
Results obtained by MIC determination 
exhibited considerably higher level of 
agreement with the expected results compared 
to results obtained by DD for all EQAS trials. As 
this situation was observed also in previous 
EQAS iterations, the EURL-AR strongly 
encourages participants to perform AST by MIC 
determination which seems to be more reliable 
and reproducible.  
One participant did not provide data on 
methicillin resistance and the EURL-AR will 
also follow up on any needs regarding the 
implementation of the detection method. 
Additional improvements are needed to 
correctly identify E. coli producing beta-
lactamases of the ESBL and AmpC-type as this 
is a priority area within the EURL-AR activities. 
We strongly encourage participants having 
problems in identifying these strains to perform 
a re-test as a training exercise and to contact 
the EURL-AR in case any discussion is needed. 
Finally, the EURL-AR is open to suggestions to 
improve future EQAS trials and invites the 
entire network to contribute with ideas for 
training courses and specific focus areas to 
expand our knowledge in antimicrobial 
resistance.
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EU Community Reference Laboratory, Antimicrobial Resistance, Kemitorvet, Building 204, DK-2800 Kgs. Lyngby, Denmark 
Ph: + 45 3588 6269, Fax: + 45 3588 6341, e-mail: licav@food.dtu.dk 
 
EURL-AR EQAS pre-notification 
EQAS 2012 FOR E. COLI, STAPHYLOCOCCI AND ENTEROCOCCI  
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight E. coli isolates, eight 
staphylococci and eight enterococci isolates. Additionally, quality control (QC) strains E. coli 
ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), S. aureus ATCC 25923 (CCM 
3953) (for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) (for MIC) will be distributed to 
new participants.  
This EQAS is specifically for NRL’s on antimicrobial resistance. Therefore, laboratories designated 
to be NRL-AR do not need to sign up to participate but are automatically regarded as participants. 
Participation is free of charge for all designated NRL-AR’s.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: eight E. coli, eight 
staphylococci, eight enterococci and for new participants also the QC strains mentioned above. 
Please provide the EQAS coordinator with documents or other information that can simplify 
customs procedures (e.g. specific text that should be written on the pro-forma invoice). To avoid 
delays, we kindly ask you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in June 2012. The protocol for this 
proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than the 7th 
of September 2012 via the password-protected website. Upon reaching the deadline, each 
participating laboratory is kindly asked to enter the password-protected website once again to 
download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
Next EQAS
Please contact me if you have comments or questions regarding the EQAS. 
: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of Salmonella and Campylobacter which will be carried out in October 2012 
Sincerely, 
 
Lina Cavaco 
EURL-AR 
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Institute  Country Ent Staph E.coli
National Food Institute Denmark x x x
Austrian Agency for Health and Food Safety Austria x x x
Institute of Public Health Belgium x x x
Veterinary Services Cyprus x x x
State Veterinary Institute Praha Czech Republic x x x
Estonian Veterinary and Food Laboratory Estonia x x x
Finnish Food Safety Authority EVIRA Finland x x x
Agence nationale de sécurité sanitaire ANSES - LERQAP France x
Agence nationale de sécurité sanitaire ANSES - Ploufragan - LERAP France x x
Agence nationale de sécurité sanitaire ANSES - Lyon France x x x
Agence nationale de sécurité sanitaire ANSES - Fougères LERMVD France x x
Federal Institute for Risk Assessment Germany x x x
Veterinary Laboratory of Chalkis Greece x x x
Central Agricultural Office Veterinary Diagnostic Directorate Hungary x x x
Central Veterinary Research Laboratory Ireland x x x
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy x x x
Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia x x x
National Food and Veterinary Risk Assessment Institute Lithuania x x x
Food and Consumer Product Safety Authority (VWA) Netherlands x x x
Central Veterinary Institute of Wageningen UR Netherlands x x x
National Veterinary Research Institute Poland x x x
National Institute of Research-Development for Microbiology and Immunology “Cantacuzino” Romania x x x
State Veterinary and Food Institute  (SVFI) Slovakia x x x
National Veterinary Institute Slovenia x x x
Laboratorio Central de Sanidad, Animal de Santa Fe Spain x x x
Laboratorio Central de Sanidad, Animal de Algete Spain x x x
National Veterinary Institute, SVA Sweden x x x
The Veterinary Laboratory Agency United Kingdom x x x
VISAVET Health Surveillance Center, Complutense University Spain x x x
Veterinærinstituttet Norway x x x
Laboratorio National de Investigacáo Veterinaria Portugal x x x
Centro nacional de Alimentacion. Agencia Espanola de Seguridad Alimentria y Nutricion Spain x x x
Public Health Laboratory Malta x x x
Nacional Diagnostic and Research Veterinary Institute Bulgaria x x x
Institute for Hygiene and Veterinary Public Health Romania x x x
Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland x x x
Centre for Infections Health Protection Agency UK x x x
Croatian Veterinary Institut Croatia X
National Food Reference Laboratory Turkey x x x
Institute for Diagnosis and Animal Health Romania x x x
Institute of Veterinary Medicine of Serbia Serbia x x x
Designated NRL-AR by the competent authority of the Member state
Not a member state of the EU
Non- NRL-AR enroled by the EURL
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Expected results for the enterococci trial (MIC-values and interpretations) 
 
Strain nr Species 
Ampicillin 
AMP 
Chloramphenicol 
CHL 
Ciprofloxacin 
CIP 
Erythromycin 
ERY 
Gentamicin 
GEN 
Linezolid 
LZD 
Streptomycin 
STR 
Quinopristin 
dalfopristin 
Q-D 
Tetracycline 
TET 
Vancomycin 
VAN 
EURL ENT 6.1 E. faecium <=2 8 <=0,5 2 <=16 2 <=64 4 <=1 <=1 
EURL ENT 6.2 E. faecium 4 4 <=0,5 1 <=16 2 <=64 4 >32 >32 
EURL ENT 6.3 E. faecalis <=2 64 1 >32 >1024 2 >2048 na >32 <=1 
EURL ENT 6.4 E. faecalis <=2 8 1 <=0,5 <=16 2 128 na <=1 4 
EURL ENT 6.5 E. faecalis <=2 64 1 <=0,5 <=16 2 2048 na >32 <=1 
EURL ENT 6.6 E. faecalis <=2 8 1 >32 <=16 1 >2048 na >32 <=1 
EURL ENT 6.7 E. faecalis <=2 8 1 <=0,5 <=16 2 128 na >32 <=1 
EURL ENT 6.8 E. faecalis <=2 8 1 >32 <=16 2 128 na >32 <=1 
            
Strain nr Species Amp CHL CIP ERY GEN LZD STR Q-D TET VAN 
EURL ENT 6.1 E. faecium S S S S S S S S S S 
EURL ENT 6.2 E. faecium S S S S S S S S R R 
EURL ENT 6.3 E. faecalis S R S R R S R na R S 
EURL ENT 6.4 E. faecalis S S S S S S S na S S 
EURL ENT 6.5 E. faecalis S R S S S S R na R S 
EURL ENT 6.6 E. faecalis S S S R S S R na R S 
EURL ENT 6.7 E. faecalis S S S S S S S na R S 
EURL ENT 6.8 E. faecalis S S S R S S S na R S 
 
  Resistant 
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Expected results for the staphylococci trial (MIC-values and interpretations) 
 
Strain nr Species 
Chloramphenicol 
CHL 
Ciprofloxacin 
CIP 
Erythromycin 
ERY 
Florfenicol 
FFN 
Cefoxitin 
FOX 
Gentamicin 
GEN 
Penicillin 
PEN 
Streptomycin 
STR 
Sulfa 
methoxazole 
SMX 
Tetracycline 
TET 
Trimethro 
prim 
TMP 
Methicillin-
resistance 
mecA 
EURL ST 6.1 S. aureus 8 1 >16 4 8 <=0,25 8 8 <=32 >32 1 POSITIVE 
EURL ST 6.2 S. aureus 8 0,5 0,5 4 4 <=0,25 8 <=4 64 <=0,5 2 NEGATIVE 
EURL ST 6.3 S. aureus 8 0,5 <=0,25 4 4 0,5 0,5 8 <=32 <=0,5 1 NEGATIVE 
EURL ST 6.4 S. aureus 8 0,25 0,5 2 4 <=0,25 0,5 8 <=32 16 1 NEGATIVE 
EURL ST 6.5 S. aureus 8 0,25 0,5 4 4 0,5 8 >64 <=32 32 1 NEGATIVE 
EURL ST 6.6 S. aureus 8 0,5 0,5 4 16 <=0,25 8 >64 <=32 >32 >32 POSITIVE 
EURL ST 6.7 S. aureus 8 0,25 0,5 4 8 0,5 8 <=4 <=32 >32 1 POSITIVE 
EURL ST 6.8 S. aureus 8 2 0,25 4 8 >16 >16 >64 256 32 1 POSITIVE 
 
Strain nr Species CHL CIP ERY FFN FOX GEN PEN STR SMX TET TMP mecA 
EURL ST 6.1 S. aureus S S R S R S R S S R S POSITIVE 
EURL ST 6.2 S. aureus S S S S S S R S S S S NEGATIVE 
EURL ST 6.3 S. aureus S S S S S S R S S S S NEGATIVE 
EURL ST 6.4 S. aureus S S S S S S R S S R S NEGATIVE 
EURL ST 6.5 S. aureus S S S S S S R R S R S NEGATIVE 
EURL ST 6.6 S. aureus S S S S R S R R S R R POSITIVE 
EURL ST 6.7 S. aureus S S S S R S R S S R S POSITIVE 
EURL ST 6.8 S. aureus S R S S R R R R R R S POSITIVE 
 
  Resistant 
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Expected results for the E. coli trial (MIC-values and interpretations) 
Strain 
nr 
Speci
es 
Ampicil
lin 
Amp 
Ceftazidi
me 
CAZ 
Chloramphen
icol 
CHL 
Ciprofloxa
cin 
CIP 
Cefotaxi
me 
CTX 
Florfeni
col 
FFN 
Cefoxiti
ne 
FOX 
Gentami
cin 
GEN 
Nalidi
xic 
acid 
NAL 
Sulfametoxa
zole 
SMX 
Streptoy
cin 
STR 
Tetracycli
ne 
TET 
Trimethrop
rim 
TMP 
Ceftiof
ur 
XNL CAZ/CLA CTX/CLA 
IP/I
PI 
ESB
L 
AMP
C 
MB
L 
EURL 
EC 6.1 E. coli >32 8 8 0,03 >4 4 >64 1 <=4 <=64 <=8 <=2 <=1 8 >4/16 >1/>16 
<4/<
1 No Yes No 
EURL 
EC 6.2 E. coli 4 0,125 8 0,25 <=0,12 4 2 1 >64 <=64 <=8 >32 <=1 <=0,5 
0,125/<=
0,5 
0,064/<0,
25 
<4/<
1 No No No 
EURL 
EC 6.3 E. coli >32 0,125 4 <=0,015 <=0,12 4 2 <=0,5 <=4 >1024 >128 >32 >32 <=0,5 
0,094/<=
0,5 
0,064/<0,
25 
<4/<
1 No No No 
EURL 
EC 6.4 E. coli >32 2 4 <=0,015 >4 4 2 <=0,5 <=4 <=64 <=8 <=2 <=1 >8 phantom 
0,064/>1
6 Syn 
<4/<
1 Yes No No 
EURL 
EC 6.5 E. coli 2 0,06 4 4 <=0,12 4 2 1 >64 >1024 >128 <=2 <=1 <=0,5 
0,064/<=
0,5 
0,032/<0,
25 
<4/<
1 No No No 
EURL 
EC 6.6 E. coli 4 0,25 8 <=0,015 <=0,12 8 2 <=0,5 <=4 <=64 <=8 <=2 <=1 <=0,5 
0,125/<=
0,5 
0,032/<0,
25 
<4/<
1 No No No 
EURL 
EC 6.7 E. coli >32 1 <=2 >4 >4 4 4 >16 >64 >1024 16 >32 >32 >8 
0,094/<0,
5 
0,064/>1
6 Syn 
<4/<
1 Yes No No 
EURL 
EC 6.8 E. coli >32 8 8 0,03 >4 8 32 1 <=4 <=64 <=8 <=2 32 8 >4/>32 >1/>16 
<4/<
1 No Yes No 
                      Strain 
nr 
Speci
es Amp CAZ CHL CIP CTX FFN FOX GEN NAL SMX STR TET TMP XNL CAZ/CLA CTX/CLA 
IP/I
PI 
ESB
L 
AMP
C 
MB
L 
EURL 
EC 6.1 E. coli R R S S R S R S S S S S S R NO SYN NO SYN 
NO 
SYN No Yes No 
EURL 
EC 6.2 E. coli S S S R S S S S R S S R S S NO SYN NO SYN 
NO 
SYN No No No 
EURL 
EC 6.3 E. coli R S S S S S S S S R R R R S NO SYN NO SYN 
NO 
SYN No No No 
EURL 
EC 6.4 E. coli R R S S R S S S S S S S S R Syn Syn 
NO 
SYN Yes No No 
EURL 
EC 6.5 E. coli S S S R S S S S R R R S S S NO SYN NO SYN 
NO 
SYN No No No 
EURL 
EC 6.6 E. coli S S S S S S S S S S S S S S NO SYN NO SYN 
NO 
SYN No No No 
EURL 
EC 6.7 E. coli R R S R R S S R R R R R R R NO SYN SYN 
NO 
SYN Yes No No 
EURL 
EC 6.8 E. coli R R S S R S R S S S S S R R NO SYN NO SYN 
NO 
SYN No Yes No 
 
  Resistant 
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M00-06-001/01.12.2011  
EURL-AR External Quality Assurance System (EQAS) 2012: 
-Escherichia coli, staphylococci and enterococci  
 
Id: «Lab_no_» 
«Name» 
«Institute__» 
«Country» 
Lyngby, 6 June 2012 
 
Dear «Name» 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2012 Upon arrival to your 
laboratory, the strains should be stored dark and at 4°C for stabs, and dark and cool for freeze-
dried strains.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-
AR EQAS are available: 
- Protocol for E. coli, staphylococci and enterococci including test forms  
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains  
 
We ask you to examine the eight E. coli, enterococci and S. aureus strains that we send to you 
by performing antimicrobial susceptibility testing. In the protocol you can find detailed de-
scription of the procedures to follow. Additionally, you can find a description of the proce-
dure to enter your results into the interactive web database. For accessing the database, you 
need this username and password: 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
Results should be entered in the database no later than 7th September 2011.Please 
acknowledge receipt of this parcel immediately upon arrival (to licav@food.dtu.dk) and do not 
hesitate to contact me for further information. 
Yours sincerely, 
Lina Cavaco 
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PROTOCOL  
For antimicrobial susceptibility testing of Escherichia coli, enterococci and staphylococci 
 
 
1    INTRODUCTION .......................................................................................................................   1
2    OBJECTIVES .............................................................................................................................   2
3    OUTLINE OF THE EQAS 2012 ...............................................................................................   2
3.1 Shipping, receipt and storage of strains .......................................................................  2
3.2 Suggested procedure for reconstitution of the lyophilised reference strains ............  2
3.3 Susceptibility testing .......................................................................................................  2
4    REPORTING OF RESULTS AND EVALUATION ...............................................................   5
5    HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE .................................   6
 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of E. coli, enterococci and staphylococci is among the 
tasks of the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The EC/Ent/Staph 
EQAS 2012 will include AST of eight E. coli, eight enterococci and eight staphylococci strains and 
AST of reference strains E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), 
S. aureus ATCC 25923 (CCM 3953) (for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) 
(for MIC).  
The above-mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
the manual ‘Subculture and Maintenance of QC Strains’ available on the EURL-AR website (see 
www.eurl-ar.eu).  
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Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to E. coli, 
enterococci and staphylococci. Further objectives are to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility of E. coli, enterococci and staphylococci reported 
to EFSA by different laboratories, and to harmonise the breakpoints for antimicrobial susceptibility 
used within the EU. 
3 OUTLINE OF THE EC/ENT/STAPH EQAS 2012 
3.1 Shipping, receipt and storage of strains 
In June 2012, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight E. coli, eight enterococci and eight staphylococci strains from the 
National Food Institute, Denmark. This parcel will also contain reference strains, but only for 
participants who did not receive them previously. All strains belong to UN3373, Biological 
substance, category B. Extended spectrum beta-lactamase (ESBL)-producing strains as well as 
methicillin resistant Staphylococcus aureus (MRSA) may be included in the selected material. The 
reference strains are shipped lyophilised, while the test strains are stab cultures. On arrival, the stab 
cultures must be subcultured, and all cultures should be kept refrigerated until testing. A suggested 
procedure for reconstitution of the lyophilised reference strains is presented below.  
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
Please refer to the document ‘Instructions for opening and reviving lyophilised cultures’ reported on 
the EURL-AR-website (see www.eurl-ar.eu). 
3.3 Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA
Participants performing minimum inhibitory concentration (MIC) determination should use the 
values listed in Tables 1, 2 and 3 for interpretation of results. These values represent the 
epidemiological cut-off values developed by EUCAST (
.  
www.eucast.org), and allow categorisation 
of bacterial isolates into two categories: Resistant or susceptible. A categorisation as intermediate is 
not accepted, and intermediate results should be interpreted as susceptible.  
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Participants using disk diffusion are recommended to interpret the results according to the 
breakpoints used routinely. Strains must be categorised resistant and susceptible. Also in this case, a 
categorization as intermediate is not accepted, and intermediate results should be interpreted as 
susceptible. 
 
3.3.1 E. coli  
Table 1: Antimicrobials recommended for AST of Escherichia coli and interpretative breakpoints 
Antimicrobials for E. coli MIC (µg/mL) R is > 
Ampicillin, AMP 8 
Cefotaxime, CTX 0.25  
Cefoxitin, FOX 8 
Ceftazidime, CAZ 0.5  
Ceftiofur, XNL 1 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.06  
Florfenicol, FFN 16 
Gentamicin, GEN 2 
Nalidixic acid, NAL 16 
Streptomycin, STR 8* 
Sulfonamides, SMX 64 
Tetracycline, TET 8 
Trimethoprim, TMP 2 
*Based on studies performed by the EURL-AR network (manuscript accepted for publication in Microbial Drug Resistance) 
 
Confirmatory tests for ESBL production is mandatory on all strains resistant to cefotaxime 
(CTX), ceftazidime (CAZ) and/or ceftiofur (XNL). 
Important notes: beta-lactam resistance 
Confirmatory test for ESBL production requires use of both cefotaxime (CTX) and ceftazidime 
(CAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (E-test 3 dilution steps difference; 
MIC CTX : CTX/CL or CAZ : CAZ/CL ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone diameter for 
either antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone 
(CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
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Confirmatory test for Metallo-beta-lactamase (MBL) production requires use of imipenem (IMI) 
and IMI/EDTA. Synergy is defined as a ≥ 3 twofold  concentration decrease in the MIC for the 
combination IMI/EDTA vs. MIC for IMI alone (E-test 3 dilution steps difference, MIC IMI : 
IMI/EDTA ratio ≥ 8; CLSI M100, Table 2A; Enterobacteriaceae). The presence of synergy 
indicates MBL production. 
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that should be verified by PCR and sequencing. 
The EURL-AR aims to harmonise with EUCAST expert rules. Accordingly, MIC values and 
relative interpretation of cefotaxime, ceftazidime and/or ceftiofur used for detection of beta-
lactamase-producing strains in this EQAS should be reported as found.  
 
3.3.2 Enterococci  
Table 2: Antimicrobials recommended for AST of Enterococcus spp. and interpretative breakpoints 
 
Antimicrobials for enterococci MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Erythromycin, ERY 4 4 
Gentamicin, GEN 32 32 
Linezolid, LZD 4 4 
Streptomycin, STR 128 512 
Quinupristin-dalfopristin (Synercid), SYN 4* Not applicable 
Tetracycline, TET 4 4 
Vancomycin, VAN 4 4 
*DANMAP 2009 (www.danmap.org)  
 
Please refer to the test forms for the species (E. faecalis or E. faecium) of the test strains.  
Important notes: identity of the test strains 
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3.3.3 Staphylococci  
Table 3: Antimicrobials recommended for AST of Staphyloccus aureus and interpretative 
breakpoints 
 
Antimicrobials for S. aureus MIC (µg/mL) R is > 
Cefoxitin, FOX 4 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Erythromycin, ERY 1 
Florfenicol, FFN 8 
Gentamicin, GEN 2 
Penicillin, PEN 0.125* 
Streptomycin, STR 16 
Sulfonamides, SMX 128 
Tetracycline, TET 1 
Trimethoprim, TMP 2 
*CLSI M100 Table 2C 
 
Some test strains may be methicillin-resistant. Confirmation of mecA presence is mandatory in 
this EQAS. For this purpose, you are welcome to use the method you prefer, and upload the result 
as ‘positive’ or ‘negative’. According to CLSI recommendations (M100, Table 2C), all MRSA 
should be regarded as resistant to all β-lactam antibiotics. 
Important notes: MRSA 
 
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the test forms, and enter your results into the interactive web database. 
In addition, we kindly ask you to report in the database the tested MIC range and/or antimicrobial 
disk content. Finally, if you did not 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than September, 7
use the cut-off values recommended in the protocol for 
interpretation of AST results, please report the breakpoints used in the database. 
th 2012. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
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If you experience difficulties in entering your results, please return the completed test forms by e-
mail, fax or mail to the National Food Institute, Denmark.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
For participants that have received additional strains as a retest for the 2012 Salm/Camp EQAS: 
Please send us the results by the document(s) ‘Retest EQAS 2012, Salmonella’ and/or ‘Retest 
EQAS 2012, Campylobacter’.  
If you have questions, please do not hesitate to contact us: 
Lina Cavaco 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204 st, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6269 
Fax: +45 3588 6341 
E-mail: licav@food.dtu.dk 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms and the breakpoint values you used.  
Enter the EURL-AR EQAS 2012 start web page (http://thor.dfvf.dk/crl), write your username and 
password in lower-cases and press enter. Your username and password are the same used in the 
previous EQAS’s arranged by The National Food Institute, Denmark. Do not hesitate to contact us 
if you experience problems with the login. 
You can browse back and forth by using the back and forward keys and by clicking on the EURL 
logo. 
Click on either “E. coli test results”, “enterococci test results” or “staphylococci test results” based 
on the results you are going to upload. The description reported below is based on Salmonella test 
result entry, but it is the exact same procedure for entering E. coli, enterococci and staphylococci 
test results. 
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Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
In the next page, you can navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing of Salmonella 
and the brand of discs, tablets, MIC trays, etc.  
Fill in the fields related to either antimicrobial disk content or tested MIC range. If you used disk 
diffusion, please upload the breakpoints used for interpretation of results. 
Click on "save and go to next page”  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli, enterococcus and staphylococcus strain. 
For E. coli strains, remember to report also the results for the ESBL detection tests. 
For S. aureus strains, remember to report also the results for presence/absence of mecA. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter the zone diameters in mm and MIC 
values in µg/ml. Remember to use the operator keys to show symbols like “equal to”, etc... If you 
do not use CLSI guidelines for AST of the reference strains, please add a comment on the method 
used. 
Click on "save and go to next page" 
This page is a menu that allows you to review the input pages and approve your input. 
Browse through the pages and make corrections if necessary. Remember to save a page if you make 
corrections. If you save a page without changes, you will see an error screen. In this case, click on 
"back" to get back to the page and "go to next page" to continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields because 
YOU CAN ONLY APPROVE ONCE! The approval blocks your data entry in the interactive 
database.  
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Enterococci, staphylococci and Escherichia coli 
TEST FORMS 
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
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TEST FORM                                                            
Which method did you use for antimicrobial susceptibility testing of enterococci in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
  Strips – E-test                                       
  Discs, tablets     
  Rosco, Neo Sensitabs  
 Brand:                            
 
How many Enterococcus spp. isolates does your laboratory annually isolate:       
How many Enterococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility:       
Comments or additional information:       
 
 
Antimicrobial  General info 
 
The relevant information 
in the two columns below 
should be reported 
 
Zone diameter (mm) 
 
Please, report breakpoint information 
only if you did not use the cut-off values 
recommended in the protocol  
 
Disk 
content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Susceptible 
(mm) 
 
Ampicillin AMP              ≤             ≥       
Chloramphenicol, CHL             ≤             ≥       
Ciprofloxacin, CIP             ≤             ≥       
Erythromycin, ERY              ≤             ≥       
Gentamicin, GEN              ≤             ≥       
Linezolid, LZD              ≤             ≥       
Streptomycin, STR              ≤             ≥       
Quin.-Dalf. (Synercid),SYN               ≤             ≥       
Tetracycline, TET              ≤             ≥       
Vancomycin, VAN              ≤             ≥       
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TEST FORM                                                            
Which method did you use for antimicrobial susceptibility testing of staphylococci in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
  Strips – E-test                                       
  Discs, tablets     
  Rosco, Neo Sensitabs 
 Brand:                            
 
How many Staphylococcus spp. isolates does your laboratory annually isolate:       
How many Staphylococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility:       
Comments or additional information:       
 
 
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
reported 
 
Zone diameter (mm) 
 
Please, report breakpoint information only 
if you did not use the cut-off values 
recommended in the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Susceptible 
(mm) 
 
Cefoxitin, FOX              ≤             ≥       
Chloramphenicol, CHL             ≤             ≥       
Ciprofloxacin, CIP              ≤             ≥       
Erythromycin, ERY              ≤             ≥       
Florfenicol, FFN              ≤             ≥       
Gentamicin, GEN              ≤             ≥       
Penicillin, PEN              ≤             ≥       
Streptomycin, STR              ≤             ≥       
Sulphonamides, SMX              ≤             ≥       
Tetracycline, TET              ≤             ≥       
Trimethoprim, TMP              ≤             ≥       
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TEST FORM       
Which method did you use for antimicrobial susceptibility testing of E. coli in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
  Strips – E-test                                       
  Discs, tablets     
  Rosco, Neo Sensitabs 
 Brand:                            
 Incubation conditions:      °C/     h 
 
How many E. coli isolates does your laboratory annually isolate:       
How many E. coli isolates does your laboratory annually test for antimicrobial susceptibility:       
Comments or additional information:       
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
reported 
 
Zone diameter (mm) 
 
Please, report breakpoint information only 
if you did not use the cut-off values 
recommended in the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Susceptible 
(mm) 
 
Ampicillin, AMP                    ≤             ≥       
Cefotaxime, CTX              ≤             ≥       
Cefoxitin, FOX             ≤             ≥       
Ceftazidime, CAZ              ≤             ≥       
Ceftiofur, XNL              ≤             ≥       
Chloramphenicol, CHL              ≤             ≥       
Ciprofloxacin CIP                   ≤             ≥       
Florfenicol, FFN              ≤             ≥       
Gentamicin, GEN              ≤             ≥       
Nalidixic acid, NAL              ≤             ≥       
Streptomycin, STR              ≤             ≥       
Sulphonamides, SMX              ≤             ≥       
Tetracycline, TET              ≤             ≥       
Trimethoprim, TMP             ≤             ≥       
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TEST FORM                                                            
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
Zone diameter 
(mm) or 
MIC-value (μg/ml) 
S / R 
Enterococci 
 
EURL ENT. 
6.X 
 
 
 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Quinupristin-Dalfopristin (Synercid),SYN                    
Tetracycline, TET                    
Vancomycin, VAN                    
TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain Enterococcus faecalis ATCC 29212  
 
 
Strain  
 
 
 
Antimicrobial  
Zone diameter (mm) or 
MIC-value (μg/ml) 
E. faecalis  
ATCC 29212 
Ampicillin, AMP        
Chloramphenicol, CHL          
Ciprofloxacin, CIP          
Erythromycin, ERY        
Gentamicin, GEN        
Linezolid, LZD        
Streptomycin, STR        
Quinupristin-Dalfopristin (Synercid), SYN       
Tetracycline, TET        
Vancomycin, VAN        
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TEST FORM                                                            
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
Zone diameter 
(mm) or 
MIC-value (μg/ml) 
S / R 
S. aureus 
 
EURL ST 6.x 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
 
 Methicillin resistance (MRSA)  Positive               Negative 
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TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain S. aureus ATCC 29213 (MIC) / 25923 (disk 
diffusion)  
 
 
Strain  
 
 
Antimicrobial  
 
Zone diameter (mm) or  
MIC-value (μg/ml) 
 
Please mark the tested strain 
 
   S. aureus ATCC 29213  
 
   S. aureus ATCC 25923 
Cefoxitin, FOX       
Chloramphenicol, CHL         
Ciprofloxacin, CIP         
Erythromycin, ERY        
Florfenicol, FFN        
Gentamicin, GEN        
Penicillin, PEN        
Streptomycin, STR        
Sulphonamides, SMX        
Tetracycline, TET        
Trimethoprim, TMP        
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TEST FORM                                                            
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
Zone diameter 
(mm) or 
MIC-value (μg/ml) 
S / R 
E. coli 
EURL EC 6.X 
Ampicillin, AMP                         
Cefotaxime, CTX                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florfenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
All strains resistant to cefotaxime (CTX), ceftazidime (CAZ) and/or ceftiofur (XNL) should be included for 
confirmatory tests for ESBL production. See further description of confirmatory tests in the protocol section 
‘3.3 E. coli’. 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX MIC ratio    
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam   
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
CAZ/CL : CAZ MIC ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam  
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
Cefoxitin, FOX MIC value   MIC value > 8   MIC value ≤ 8  Zone diameter  
 D ≤ 19 mm  
 D > 19 mm 
Imipenem, IMI MIC value   MIC value > 1   MIC value ≤ 1 
 Confirmed ESBL 
 Confirmed AmpC 
 Confirmed Metallo beta-lactamase IMI/E : IMI MIC ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
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Comments:       
 
TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain E. coli ATCC 25922 
 
Strain 
 
 
 
Antimicrobial  
 
Zone diameter (mm) or  
MIC-value (μg/ml) 
E. coli ATCC 25922 
 
 
 
 
Amoxicillin, AMX       
Ampicillin, AMP       
Cefotaxime, CTX       
Cefoxitin, FOX       
Ceftazidime, CAZ       
Ceftiofur, XNL       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Florfenicol, FFN       
Gentamicin, GEN       
Nalidixic Acid, NAL       
Streptomycin, STR       
Sulfisoxazole, FIS*       
Tetracycline, TET       
Trimethoprim, TMP       
Imipenem, IMI       
 
*The antimicrobial which is mentioned in the CLSI M100 performance standard as representative 
for the sulfonamides concerning acceptable limits for quality control strains (CLSI M100, Table 3) 
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages)
1.4 Important Considerations 
: A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
 Periodically perform colony counts to check the inoculum preparation procedure 
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 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
Preparation of stock cultures 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
Working cultures 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
Weekly vs. daily testing  
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
  
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing.  
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DAILY MIC QC CHART 
 
Reference: CLSI M7-A8, page 44 
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WEEKLY MIC QC CHART 
 
 
 Reference: CLSI M7-A8, page 45 
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Appendix 5a. Breakpoints used routinely in disk diffusion - Enterococci
Disk R val I val S val
content <= = >=
(μg) (mm) (mm) (mm)
Ampicillin, AMP 57 25 16 17
26 10 16 17
18 10 16 17
54 10 16 17
Chloramphenicol, CHL 57 30 12 13-17 18
26 30 12 13-17 18
18 30 12 18
54 30 12 13-17 18
Ciprofloxacin, CIP 57 10 15 16-20 21
26 5 15 16-20 21
18 5 15 21
54 5 15 16-20 21
Erythromycin, ERY 57 30 13 14-22 23
26 15 13 14-22 23
18 15 13 23
54 15 13 14-22 23
Gentamicin, GEN 57 30 12 13-14 15
26 10 12 13-14 15
18 10
54 10 12 13-14 15
Linezolid, LZD 57 30 20 21-22 23
26 30 20 21-22 23
18 30 20 23
54 30 20 0 21
Quinu-dalfo-pristin, Q-D 57 15 15 16-18 19
26 15 20 22
18 15 15 19
Streptomycin, STR 57 25 11 12-14 15
26 300 6 7-9 10
18 10
54 10 11 12-14 15
Tetracycline, TET 57 30 14 15-18 19
26 30 14 15-18 19
18 30 14 19
54 30 14 15-18 19
Vancomycin, VAN 57 30 14 15-16 17
26 30 14 15-16 17
18 30 14 17
54 30 14 15-16 17
Antibiotic Lab nr
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Appendix 5b. Breakpoints used routinely in disk diffusion – Staphylococci
Disk R val I val S val
content <= = >=
(μg) (mm) (mm) (mm)
Cefoxitin, FOX 57 30 21 22
13 30 21 22
18 30 22 22
14 27
56 30 19 20
28 30 21 - 22
54 30 14 15-17 18
Chloramphenicol, CHL 57 30 12 13-17 18
18 30 18 18
14 30 22
56 30 12 13-17 18
28 30 17 - 18
15 18 22
54 30 12 13-17 18
Ciprofloxacin, CIP 57 10 15 16-20 21
13 5 15 21
18 5 20 20
14 5 22
56 5 15 16-20 21
28 5 19 - 20
15 21 22
54 5 15 16-20 21
Erythromycin, ERY 57 30 13 14-22 23
13 15 13 23
18 15 18 21
14 15 UI 22
56 15 13 14-22 23
28 15 17 18 - 20 21
15 16 22
54 15 13 14-22 23
Florfenicol, FFN 57 30
18 30
56 30 14 15-18 19
15 14 19
54 30 14 15-17 19
Gentamicin, GEN 57 30 12 13-14 15
13 10 12 15
18 10 18 18
14 15 20
56 10 12 13-14 15
28 10 17 - 18
15 19 20
54 10 12 13-14 15
Antibiotic Lab nr
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Disk R val I val S val
content <= = >=
(μg) (mm) (mm) (mm)
Antibiotic Lab nr
Penicillin, PEN 57 10 28 29
13 10units 28 29
18 10 28 29
14 6 29
56 10 28 29
28 1U 25 - 26
15 28 29
54 10U 28 - 29
Streptomycin, STR 57 25 11 12-14 15
18 10
56 10 11 12-14 15
15 12 15
54 10 11 12-14 15
Sulfamethoxazole, SMX 57 25 12 13-16 17
13 250 12 17
18 300 12 17
56 23,75 12 13-16 17
15 11 17
Tetracycline, TET 57 30 14 15-18 19
13 30 12 16
18 30 19 22
14 30 UI 19
56 30 14 15-18 19
28 30 18 19 - 21 22
15 16 19
54 30 14 15-18 19
Trimethoprim, TMP 57 5 10 11-15 16
18 5 14 17
56 5 10 11-15 16
28 5 13 14 - 16 17
15 11 16
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Appendix 5c. Breakpoints used routinely in disk diffusion – E. coli
Disk Test 
range
R val I val S val
content for MIC <= = >=
(μg) (μg/mL) (mm) (mm) (mm)
Ampicillin, AMP 57 25 13 14-16 17
28 10 13 14-16 17
18 10 13 14-16 17
54 10 13 14-16 17
17 10 13 14-16 17
Cefotaxime, CTX 57 30 22 23-25 26
14 30 26
28 30 22 23-25 26
15 30 22 23-25 26
18 30 27 28
54 30 14 15-22 23
17 30 14 15-22 23
Ceftazidime, CAZ 57 30 17 18-20 21
14 30 26
28 30 17 18-20 21
15 30 20 21-25 26
18 30 22 23
54 30 14 15-17 18
17 30 14 15-17 18
Ceftiofur, XNL 57 30
14 30 21
15 30 17 18-20 21
18 30 17 18-20 21
17 30 17 18-20 21
Chloramphenicol, CHL 57 30 12 13-17 18
28 30 12 13-17 18
15 30 18 19-21 22
18 30 12 13-17 18
54 30 12 13-17 18
17 30 12 13-17 18
Ciprofloxacin, CIP 57 10 20 21-30 31
14 5 25
28 5 15 16-20 21
18 5 29 30
54 5 15 16-20 21
17 5 15 16-20 21
Florphenicol, FFN 57 30
15 30 14 15-18 19
18 30 14 15-18 19
54 30 14 15-18 19
17 30 14 15-18 19
Gentamicin, GEN 57 30 12 13-14 15
14 15 18
28 10 12 13-14 15
15 15 15 16-17 18
18 10 12 13-14 15
54 10 12 13-14 15
17 10 12 13-14 15
Nalidixic acid, NAL 57 30 13 14-18 19
14 30 20
28 30 13 14-18 19
15 30 14 15-19 20
18 30 13 14-18 19
54 30 13 14-18 19
17 30 13 14-18 19
Antibiotic Lab nr
Appendix 5c, page 2 of 2
Disk Test 
range
R val I val S val
content for MIC <= = >=
(μg) (μg/mL) (mm) (mm) (mm)
Antibiotic Lab nr
Streptomycin, STR 57 25 11 12-14 15
28 10 11 12-14 15
15 10 12 13-14 15
18 10 11 12-14 15
54 10 11 12-14 15
17 10 11 12-14 15
Sulfamethoxazole, SMX 57 25 12 13-16 17
28 250 12 13-16 17
18 300 12 13-16 17
17 300 12 13-16 17
Tetracycline,TET 57 30 11 12-14 15
14 30UI 19
28 30 11 12-14 15
15 30 16 17-18 19
18 30 11 12-14 15
54 30 14 15-18 19
17 30 11 12-14 15
Trimethoprim, TMP 57 5 10 11-15 16
28 5 10 11-15 16
15 5 11 12-15 16
18 5 10 11-15 16
17 1.25/23.75 10 11-15 16
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Antimicrobial MIC*
Ampicillin, AMP 0.5 - 2
Chloramphenicol, CHL 4 - 16
Ciprofloxacin, CIP 0.25 - 2
Erythromycin, ERY 1 - 4
Gentamicin, GEN 4 - 16
Linezolid, LZD 1 - 4
Quinupristin-dalfopristin, Q-D 2 - 8
Tetracycline, TET 8 - 32
Vancomycin, VAN 1 - 4
ATCC 29213 
Antimicrobial Disk diffusion* ROSCO MIC* 
Cefoxitin 23-29 23-29 1-4
Chloramphenicol, CHL 19 - 26 19-26 2 - 16
Ciprofloxacin, CIP 22 - 30 22-30 0.12 - 0.5
Erythromycin, ERY 22 - 30 22-30 0.25 - 1
Florfenicol, FFN None None 2 - 8
Gentamicin, GEN 19 - 27 19-27 0.12 - 1
Penicillin, PEN 26 - 37 26-37 0.25 - 2
Streptomycin, STR 14 - 22 14-22 None
Sulphonamides, SMX 24 - 34 23-33 32 - 128
Tetracycline, TET 24 - 30 24-30 0.12 - 1
Trimethoprim, TMP 19 - 26 19-26 1-4
Antimicrobial Disk diffusion* MIC*
Ampicillin, AMP 16 - 22 2 - 8
Cefotaxime, CTX 29 - 35 0.03 - 0.12
Cefoxitin 23-29 2-8
Ceftazidime, CAZ 25 - 32 0.06 - 0.5
Ceftiofur, XNL 26 - 31 0.25 - 1
Chloramphenicol, CHL 21 - 27 2 - 8
Ciprofloxacin, CIP 30 - 40 0.004 - 0.015
Gentamicin, GEN 19 - 26 0.25 - 1
Imipenem 26-32 0.06-0.25
Nalidixic acid, NAL 22 - 28 1 - 4
Streptomycin, STR 12-20 4 - 16
Sulphonamides, SMX 15 - 23 8 - 32
Tetracycline, TET 18 - 25 0.5 - 2
Trimethoprim, TMP 21 - 28 0.5 - 2
Appendix 6. Acceptable ranges for the quality control strains
Enterococcus faecalis  ATCC 29212
Escherichia coli  ATCC 25922
ATCC 25923
*MIC ranges (in  µg/ml)  and disk diffusion ranges (in mm) according to CLSI M100-S21 with the 
exception of the MIC range for streptomycin which is according to Sensititre. In addition, the range for 
ciprofloxacin is extended to include 0.016 µg/ml
Staphylococcus aureus
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Test results from reference strain Enterococcus faecalis ATCC 29212
Lab no Antib Operator Value Low limit High limit Mark Method
1 Ampicillin , AMP <= 2 2 1 MIC
1 Chloramphenicol, CHL = 8 4 16 1 MIC
1 Ciprofloxacin , CIP = 1 2 1 MIC
1 Erythromycin, ERY = 1 1 4 1 MIC
1 Gentamicin, GEN <= 16 4 16 1 MIC
1 Linezolid, LZD = 2 1 4 1 MIC
1 Quinu-dalfo-pristin, Q-D = 8 2 8 1 MIC
1 Streptomycin, STR = 128 0 256 0 MIC
1 Tetracycline, TET = 16 8 32 1 MIC
1 Vancomycin, VAN = 4 1 4 1 MIC
2 Ampicillin , AMP = 2 2 1 MIC
2 Chloramphenicol, CHL = 8 4 16 1 MIC
2 Ciprofloxacin , CIP = 1 2 1 MIC
2 Erythromycin, ERY = 2 1 4 1 MIC
2 Gentamicin, GEN = 16 4 16 1 MIC
2 Linezolid, LZD = 2 1 4 1 MIC
2 Quinu-dalfo-pristin, Q-D = 8 2 8 1 MIC
2 Streptomycin, STR = 128 0 256 0 MIC
2 Tetracycline, TET = 32 8 32 1 MIC
2 Vancomycin, VAN = 4 1 4 1 MIC
6 Chloramphenicol, CHL = 8 4 16 1 MIC
6 Ciprofloxacin , CIP = 0.25 2 1 MIC
6 Erythromycin, ERY = 1 1 4 1 MIC
6 Linezolid, LZD = 2 1 4 1 MIC
6 Quinu-dalfo-pristin, Q-D = 2 2 8 1 MIC
6 Tetracycline, TET = 8 8 32 1 MIC
6 Vancomycin, VAN = 1 1 4 1 MIC
9 Ampicillin , AMP = 1 2 1 MIC
9 Chloramphenicol, CHL = 8 4 16 1 MIC
9 Ciprofloxacin , CIP = 0.5 2 1 MIC
9 Erythromycin, ERY = 2 1 4 1 MIC
9 Gentamicin, GEN = 8 4 16 1 MIC
9 Linezolid, LZD = 2 1 4 1 MIC
9 Streptomycin, STR = 64 0 256 0 MIC
9 Tetracycline, TET = 16 8 32 1 MIC
9 Vancomycin, VAN = 2 1 4 1 MIC
11 Ampicillin , AMP = 1 2 1 MIC
11 Chloramphenicol, CHL = 4 4 16 1 MIC
11 Erythromycin, ERY = 1 1 4 1 MIC
11 Gentamicin, GEN = 4 4 16 1 MIC
11 Linezolid, LZD = 1 1 4 1 MIC
11 Streptomycin, STR = 64 0 256 0 MIC
11 Tetracycline, TET = 16 8 32 1 MIC
11 Vancomycin, VAN = 2 1 4 1 MIC
12 Ampicillin , AMP = 1 2 1 MIC
12 Chloramphenicol, CHL = 4 4 16 1 MIC
12 Ciprofloxacin , CIP = 1 2 1 MIC
12 Erythromycin, ERY = 1 1 4 1 MIC
12 Gentamicin, GEN = 8 4 16 1 MIC
12 Linezolid, LZD = 2 1 4 1 MIC
12 Streptomycin, STR = 64 0 256 0 MIC
12 Tetracycline, TET = 16 8 32 1 MIC
12 Vancomycin, VAN = 4 1 4 1 MIC
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Lab no Antib Operator Value Low limit High limit Mark Method
16 Ampicillin , AMP = 1 2 1 MIC
16 Chloramphenicol, CHL = 8 4 16 1 MIC
16 Ciprofloxacin , CIP = 1 2 1 MIC
16 Erythromycin, ERY = 2 1 4 1 MIC
16 Gentamicin, GEN = 16 4 16 1 MIC
16 Linezolid, LZD = 2 1 4 1 MIC
16 Quinu-dalfo-pristin, Q-D = 8 2 8 1 MIC
16 Streptomycin, STR = 128 0 256 0 MIC
16 Tetracycline, TET = 16 8 32 1 MIC
16 Vancomycin, VAN = 4 1 4 1 MIC
17 Ampicillin , AMP = 2 2 1 MIC
17 Chloramphenicol, CHL = 8 4 16 1 MIC
17 Ciprofloxacin , CIP = 1 2 1 MIC
17 Erythromycin, ERY = 1 1 4 1 MIC
17 Gentamicin, GEN = 8 4 16 1 MIC
17 Linezolid, LZD = 2 1 4 1 MIC
17 Quinu-dalfo-pristin, Q-D > 4 2 8 1 MIC
17 Streptomycin, STR = 128 0 256 0 MIC
17 Tetracycline, TET = 32 8 32 1 MIC
17 Vancomycin, VAN = 4 1 4 1 MIC
19 Chloramphenicol, CHL = 8 4 16 1 MIC
19 Ciprofloxacin , CIP = 1 2 1 MIC
19 Erythromycin, ERY = 2 1 4 1 MIC
19 Gentamicin, GEN = 16 4 16 1 MIC
19 Streptomycin, STR = 128 0 256 0 MIC
19 Tetracycline, TET = 16 8 32 1 MIC
19 Vancomycin, VAN = 4 1 4 1 MIC
20 Ampicillin , AMP = 2 2 1 MIC
20 Chloramphenicol, CHL = 8 4 16 1 MIC
20 Ciprofloxacin , CIP = 1 2 1 MIC
20 Erythromycin, ERY = 1 1 4 1 MIC
20 Gentamicin, GEN = 8 4 16 1 MIC
20 Linezolid, LZD = 2 1 4 1 MIC
20 Quinu-dalfo-pristin, Q-D = 4 2 8 1 MIC
20 Streptomycin, STR = 64 0 256 0 MIC
20 Tetracycline, TET = 32 8 32 1 MIC
20 Vancomycin, VAN = 4 1 4 1 MIC
21 Chloramphenicol, CHL = 4 4 16 1 MIC
21 Ciprofloxacin , CIP = 0.5 2 1 MIC
21 Erythromycin, ERY = 1 1 4 1 MIC
21 Gentamicin, GEN = 8 4 16 1 MIC
21 Linezolid, LZD = 2 1 4 1 MIC
21 Quinu-dalfo-pristin, Q-D = 4 2 8 1 MIC
21 Tetracycline, TET = 16 8 32 1 MIC
21 Vancomycin, VAN = 2 1 4 1 MIC
22 Ampicillin , AMP = 1 2 1 MIC
22 Chloramphenicol, CHL = 8 4 16 1 MIC
22 Erythromycin, ERY = 2 1 4 1 MIC
22 Gentamicin, GEN = 8 4 16 1 MIC
22 Linezolid, LZD = 2 1 4 1 MIC
22 Streptomycin, STR = 64 0 256 0 MIC
22 Tetracycline, TET = 32 8 32 1 MIC
22 Vancomycin, VAN = 4 1 4 1 MIC
23 Chloramphenicol, CHL = 8 4 16 1 MIC
23 Ciprofloxacin , CIP = 1 2 1 MIC
23 Erythromycin, ERY = 2 1 4 1 MIC
23 Tetracycline, TET = 32 8 32 1 MIC
23 Vancomycin, VAN = 4 1 4 1 MIC
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25 Ampicillin , AMP <= 1 2 1 MIC
25 Chloramphenicol, CHL = 8 4 16 1 MIC
25 Ciprofloxacin , CIP = 1 2 1 MIC
25 Erythromycin, ERY = 2 1 4 1 MIC
25 Gentamicin, GEN = 16 4 16 1 MIC
25 Linezolid, LZD = 2 1 4 1 MIC
25 Quinu-dalfo-pristin, Q-D = 8 2 8 1 MIC
25 Streptomycin, STR = 128 0 256 0 MIC
25 Tetracycline, TET = 32 8 32 1 MIC
25 Vancomycin, VAN = 4 1 4 1 MIC
29 Ampicillin , AMP = 0.5 2 1 MIC
29 Chloramphenicol, CHL = 4 4 16 1 MIC
29 Ciprofloxacin , CIP = 0.25 2 1 MIC
29 Erythromycin, ERY = 2 1 4 1 MIC
29 Gentamicin, GEN = 4 4 16 1 MIC
29 Tetracycline, TET = 32 8 32 1 MIC
29 Vancomycin, VAN = 1 1 4 1 MIC
33 Ampicillin , AMP = 1 2 1 MIC
33 Chloramphenicol, CHL = 8 4 16 1 MIC
33 Erythromycin, ERY = 1 1 4 1 MIC
33 Gentamicin, GEN = 4 4 16 1 MIC
33 Linezolid, LZD = 1 1 4 1 MIC
33 Streptomycin, STR = 64 0 256 0 MIC
33 Tetracycline, TET = 16 8 32 1 MIC
33 Vancomycin, VAN = 2 1 4 1 MIC
34 Ampicillin , AMP = 1 2 1 MIC
34 Chloramphenicol, CHL = 8 4 16 1 MIC
34 Ciprofloxacin , CIP = 0.5 2 1 MIC
34 Erythromycin, ERY = 2 1 4 1 MIC
34 Gentamicin, GEN = 16 4 16 1 MIC
34 Linezolid, LZD = 2 1 4 1 MIC
34 Quinu-dalfo-pristin, Q-D > 4 2 8 1 MIC
34 Streptomycin, STR = 128 0 256 0 MIC
34 Tetracycline, TET = 16 8 32 1 MIC
34 Vancomycin, VAN = 2 1 4 1 MIC
36 Ampicillin , AMP = 1 2 1 MIC
36 Chloramphenicol, CHL = 4 4 16 1 MIC
36 Erythromycin, ERY = 4 1 4 1 MIC
36 Gentamicin, GEN = 8 4 16 1 MIC
36 Linezolid, LZD = 1 1 4 1 MIC
36 Streptomycin, STR = 64 0 256 0 MIC
36 Tetracycline, TET = 32 8 32 1 MIC
36 Vancomycin, VAN >= 1 1 4 1 MIC
37 Ampicillin , AMP = 1 2 1 AGA
37 Chloramphenicol, CHL = 8 4 16 1 AGA
37 Ciprofloxacin , CIP = 1 2 1 AGA
37 Erythromycin, ERY = 1 1 4 1 AGA
37 Gentamicin, GEN = 8 4 16 1 AGA
37 Streptomycin, STR = 16 0 256 0 AGA
37 Tetracycline, TET = 16 8 32 1 AGA
37 Vancomycin, VAN = 2 1 4 1 AGA
39 Ampicillin , AMP = 0.5 2 1 MIC
39 Chloramphenicol, CHL = 8 4 16 1 MIC
39 Erythromycin, ERY = 2 1 4 1 MIC
39 Gentamicin, GEN = 8 4 16 1 MIC
39 Linezolid, LZD = 2 1 4 1 MIC
39 Tetracycline, TET = 16 8 32 1 MIC
39 Vancomycin, VAN = 2 1 4 1 MIC
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40 Chloramphenicol, CHL = 8 4 16 1 MIC
40 Ciprofloxacin , CIP = 0.25 2 1 MIC
40 Erythromycin, ERY = 1 1 4 1 MIC
40 Gentamicin, GEN = 16 4 16 1 MIC
40 Linezolid, LZD = 2 1 4 1 MIC
40 Tetracycline, TET = 32 8 32 1 MIC
40 Vancomycin, VAN = 2 1 4 1 MIC
41 Ampicillin , AMP = 1 2 1 MIC
41 Chloramphenicol, CHL = 8 4 16 1 MIC
41 Ciprofloxacin , CIP = 1 2 1 MIC
41 Erythromycin, ERY = 1 1 4 1 MIC
41 Gentamicin, GEN = 8 4 16 1 MIC
41 Linezolid, LZD = 2 1 4 1 MIC
41 Quinu-dalfo-pristin, Q-D = 4 2 8 1 MIC
41 Streptomycin, STR <= 1000 0 256 0 MIC
41 Tetracycline, TET = 8 8 32 1 MIC
41 Vancomycin, VAN = 2 1 4 1 MIC
42 Ampicillin , AMP <= 2 2 1 MIC
42 Chloramphenicol, CHL = 16 4 16 1 MIC
42 Ciprofloxacin , CIP = 1 2 1 MIC
42 Erythromycin, ERY = 2 1 4 1 MIC
42 Gentamicin, GEN <= 128 4 16 1 MIC
42 Linezolid, LZD = 2 1 4 1 MIC
42 Quinu-dalfo-pristin, Q-D = 8 2 8 1 MIC
42 Streptomycin, STR <= 128 0 256 0 MIC
42 Tetracycline, TET = 32 8 32 1 MIC
42 Vancomycin, VAN = 2 1 4 1 MIC
58 Ampicillin , AMP = 1 2 1 MIC
58 Chloramphenicol, CHL = 4 4 16 1 MIC
58 Ciprofloxacin , CIP = 1 2 1 MIC
58 Erythromycin, ERY = 2 1 4 1 MIC
58 Gentamicin, GEN = 16 4 16 1 MIC
58 Linezolid, LZD = 2 1 4 1 MIC
58 Quinu-dalfo-pristin, Q-D = 8 2 8 1 MIC
58 Streptomycin, STR <= 512 0 256 0 MIC
58 Tetracycline, TET = 16 8 32 1 MIC
58 Vancomycin, VAN = 4 1 4 1 MIC
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Test results from Staphylococcus aureus reference strains
Lab no Antib Operator Value Low limit High limit Mark Method ATCC 
29213
ATCC 
25923
1 Cefoxitin, FOX = 4 1 4 1 MIC x
1 Chloramphenicol, CHL = 8 2 16 1 MIC x
1 Ciprofloxacin, CIP = 0.25 1 MIC x
1 Erythromycin, ERY = 0.5 1 1 MIC x
1 Florfenicol, FFN = 4 2 8 1 MIC x
1 Gentamicin, GEN <= 0.25 1 1 MIC x
1 Penicillin, PEN = 0.5 2 1 MIC x
1 Streptomycin, STR = 8 0 256 0 MIC x
1 Tetracycline, TET <= 0.5 1 1 MIC x
1 Trimethoprim, TMP = 2 1 4 1 MIC x
2 Cefoxitin, FOX = 4 1 4 1 MIC x
2 Chloramphenicol, CHL = 8 2 16 1 MIC x
2 Ciprofloxacin, CIP = 0.5 1 MIC x
2 Erythromycin, ERY = 0.5 1 1 MIC x
2 Gentamicin, GEN <= 1 1 1 MIC x
2 Penicillin, PEN = 0.25 2 1 MIC x
2 Streptomycin, STR <= 4 0 256 0 MIC x
2 Tetracycline, TET <= 0.5 1 1 MIC x
2 Trimethoprim, TMP <= 2 1 4 1 MIC x
4 Cefoxitin, FOX = 29.92 23 29 0 ROS x
4 Chloramphenicol, CHL = 22.95 23 30 0 ROS x
4 Ciprofloxacin, CIP = 25.52 21 29 1 ROS x
4 Erythromycin, ERY = 26.22 26 33 1 ROS x
4 Florfenicol, FFN = 25.03 0 256 0 ROS x
4 Gentamicin, GEN = 25.21 25 32 1 ROS x
4 Sulfisoxazole, FIS = 25.31 26 34 0 ROS x
4 Tetracycline, TET = 27.59 23 33 1 ROS x
4 Trimethoprim, TMP = 21.15 19 25 1 ROS x
6 Cefoxitin, FOX = 2 1 4 1 MIC x
6 Chloramphenicol, CHL = 8 2 16 1 MIC x
6 Ciprofloxacin, CIP = 0.5 1 MIC x
6 Erythromycin, ERY = 0.5 1 1 MIC x
6 Gentamicin, GEN < 1 1 1 MIC x
6 Penicillin, PEN = 0.5 2 1 MIC x
6 Streptomycin, STR = 8 0 256 0 MIC x
6 Tetracycline, TET = 1 1 1 MIC x
6 Trimethoprim, TMP < 2 1 4 1 MIC x
9 Cefoxitin, FOX = 4 1 4 1 MIC x
9 Chloramphenicol, CHL = 4 2 16 1 MIC x
9 Ciprofloxacin, CIP = 0.25 1 MIC x
9 Erythromycin, ERY = 0.5 1 1 MIC x
9 Florfenicol, FFN = 4 2 8 1 MIC x
9 Gentamicin, GEN = 1 1 1 MIC x
9 Penicillin, PEN = 0.5 2 1 MIC x
9 Streptomycin, STR = 4 0 256 0 MIC x
9 Sulfisoxazole, FIS = 64 32 128 1 MIC x
9 Tetracycline, TET = 0.5 1 1 MIC x
9 Trimethoprim, TMP = 2 1 4 1 MIC x
11 Chloramphenicol, CHL = 8 2 16 1 MIC x
11 Ciprofloxacin, CIP = 0.25 1 MIC x
11 Erythromycin, ERY = 0.5 1 1 MIC x
11 Gentamicin, GEN <= 0.5 1 1 MIC x
11 Penicillin, PEN = 1 2 1 MIC x
11 Tetracycline, TET <= 0.5 1 1 MIC x
11 Trimethoprim, TMP = 2 1 4 1 MIC x
12 Cefoxitin, FOX = 4 1 4 1 MIC x
12 Chloramphenicol, CHL = 8 2 16 1 MIC x
12 Ciprofloxacin, CIP = 0.25 1 MIC x
12 Erythromycin, ERY = 0.5 1 1 MIC x
12 Florfenicol, FFN <= 4 2 8 1 MIC x
12 Gentamicin, GEN <= 0.5 1 1 MIC x
12 Penicillin, PEN = 0.25 2 1 MIC x
12 Streptomycin, STR = 8 0 256 0 MIC x
12 Tetracycline, TET <= 0.5 1 1 MIC x
12 Trimethoprim, TMP = 2 1 4 1 MIC x
13 Cefoxitin, FOX = 28 23 29 1 DD x
13 Ciprofloxacin, CIP = 29 22 30 1 DD x
13 Erythromycin, ERY = 28 22 30 1 DD x
13 Gentamicin, GEN = 26 19 27 1 DD x
13 Penicillin, PEN = 37 26 37 1 DD x
13 Sulfisoxazole, FIS = 24 24 30 1 DD x
13 Tetracycline, TET = 28 24 34 1 DD x
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14 Cefoxitin, FOX = 32 23 29 0 DD x
14 Chloramphenicol, CHL = 24 16 26 1 DD x
14 Ciprofloxacin, CIP = 28 22 30 1 DD x
14 Erythromycin, ERY = 30 22 30 1 DD x
14 Gentamicin, GEN = 30 19 27 0 DD x
14 Penicillin, PEN = 40 26 37 0 DD x
14 Tetracycline, TET = 31 24 34 1 DD x
15 Cefoxitin, FOX = 29 23 29 1 DD x
15 Chloramphenicol, CHL = 23 16 26 1 DD x
15 Erythromycin, ERY = 30 22 30 1 DD x
15 Gentamicin, GEN = 27 19 27 1 DD x
15 Penicillin, PEN = 37 26 37 1 DD x
15 Tetracycline, TET = 31 24 34 1 DD x
17 Cefoxitin, FOX = 4 1 4 1 MIC x
17 Chloramphenicol, CHL = 8 2 16 1 MIC x
17 Ciprofloxacin, CIP = 0.5 1 MIC x
17 Erythromycin, ERY = 0.5 1 1 MIC x
17 Florfenicol, FFN = 4 2 8 1 MIC x
17 Gentamicin, GEN <= 1 1 1 MIC x
17 Penicillin, PEN = 0.5 2 1 MIC x
17 Streptomycin, STR = 8 0 256 0 MIC x
17 Sulfisoxazole, FIS <= 64 32 128 1 MIC x
17 Tetracycline, TET <= 0.5 1 1 MIC x
17 Trimethoprim, TMP <= 2 1 4 1 MIC x
18 Cefoxitin, FOX = 26 23 29 1 DD x
18 Chloramphenicol, CHL = 23 16 26 1 DD x
18 Ciprofloxacin, CIP = 24 22 30 1 DD x
18 Erythromycin, ERY = 25 22 30 1 DD x
18 Florfenicol, FFN = 25 0 256 0 DD x
18 Gentamicin, GEN = 22 19 27 1 DD x
18 Penicillin, PEN = 32 26 37 1 DD x
18 Streptomycin, STR = 15 14 22 1 DD x
18 Sulfisoxazole, FIS = 24 24 30 1 DD x
18 Tetracycline, TET = 27 24 34 1 DD x
18 Trimethoprim, TMP = 21 19 26 1 DD x
19 Cefoxitin, FOX = 4 1 4 1 MIC x
19 Chloramphenicol, CHL = 4 2 16 1 MIC x
19 Ciprofloxacin, CIP = 0.25 1 MIC x
19 Erythromycin, ERY = 0.5 1 1 MIC x
19 Gentamicin, GEN = 1 1 1 MIC x
19 Penicillin, PEN = 0.25 2 1 MIC x
19 Streptomycin, STR = 4 0 256 0 MIC x
19 Sulfisoxazole, FIS = 64 32 128 1 MIC x
19 Tetracycline, TET = 0.5 1 1 MIC x
19 Trimethoprim, TMP = 2 1 4 1 MIC x
20 Cefoxitin, FOX = 4 1 4 1 MIC x
20 Chloramphenicol, CHL = 16 2 16 1 MIC x
20 Ciprofloxacin, CIP = 0.5 1 MIC x
20 Erythromycin, ERY = 1 1 1 MIC x
20 Gentamicin, GEN <= 1 1 1 MIC x
20 Penicillin, PEN = 2 2 1 MIC x
20 Streptomycin, STR = 8 0 256 0 MIC x
20 Sulfisoxazole, FIS = 128 32 128 1 MIC x
20 Tetracycline, TET = 1 1 1 MIC x
20 Trimethoprim, TMP <= 2 1 4 1 MIC x
21 Cefoxitin, FOX = 4 1 4 1 MIC x
21 Chloramphenicol, CHL = 8 2 16 1 MIC x
21 Ciprofloxacin, CIP = 0.25 1 MIC x
21 Erythromycin, ERY = 0.5 1 1 MIC x
21 Gentamicin, GEN = 1 1 1 MIC x
21 Penicillin, PEN = 0.25 2 1 MIC x
21 Sulfisoxazole, FIS = 64 32 128 1 MIC x
21 Tetracycline, TET = 0.5 1 1 MIC x
21 Trimethoprim, TMP = 2 1 4 1 MIC x
22 Chloramphenicol, CHL = 8 2 16 1 MIC x
22 Ciprofloxacin, CIP = 0.5 1 MIC x
22 Erythromycin, ERY = 0.5 1 1 MIC x
22 Gentamicin, GEN = 1 1 1 MIC x
22 Penicillin, PEN = 0.5 2 1 MIC x
22 Streptomycin, STR < 4 0 256 0 MIC x
22 Sulfisoxazole, FIS = 128 32 128 1 MIC x
22 Tetracycline, TET = 1 1 1 MIC x
22 Trimethoprim, TMP < 2 1 4 1 MIC x
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23 Cefoxitin, FOX = 4 1 4 1 MIC x
23 Chloramphenicol, CHL = 8 2 16 1 MIC x
23 Ciprofloxacin, CIP = 0.5 1 MIC x
23 Erythromycin, ERY = 0.5 1 1 MIC x
23 Gentamicin, GEN < 1 1 1 MIC x
23 Penicillin, PEN = 0.25 2 1 MIC x
23 Streptomycin, STR < 4 0 256 0 MIC x
23 Sulfisoxazole, FIS < 64 32 128 1 MIC x
23 Tetracycline, TET < 0.5 1 1 MIC x
23 Trimethoprim, TMP < 2 1 4 1 MIC x
25 Erythromycin, ERY = 0.5 1 1 MIC x
25 Penicillin, PEN = 1 2 1 MIC x
25 Streptomycin, STR = 4 0 256 0 MIC x
25 Tetracycline, TET = 0.5 1 1 MIC x
26 Cefoxitin, FOX = 4 1 4 1 MIC x
26 Chloramphenicol, CHL = 8 2 16 1 MIC x
26 Ciprofloxacin, CIP = 0.5 1 MIC x
26 Erythromycin, ERY = 0.5 1 1 MIC x
26 Florfenicol, FFN = 4 2 8 1 MIC x
26 Gentamicin, GEN = 0.5 1 1 MIC x
26 Penicillin, PEN = 0.5 2 1 MIC x
26 Streptomycin, STR = 8 0 256 0 MIC x
26 Sulfisoxazole, FIS = 64 32 128 1 MIC x
26 Tetracycline, TET = 1 1 1 MIC x
26 Trimethoprim, TMP = 2 1 4 1 MIC x
29 Chloramphenicol, CHL = 4 2 16 1 MIC x
29 Ciprofloxacin, CIP = 0.5 1 MIC x
29 Erythromycin, ERY = 0.5 1 1 MIC x
29 Gentamicin, GEN = 0.5 1 1 MIC x
29 Penicillin, PEN = 0.25 2 1 MIC x
29 Tetracycline, TET = 0.5 1 1 MIC x
29 Trimethoprim, TMP = 2 1 4 1 MIC x
30 Cefoxitin, FOX <= 6 1 4 1 MIC x
30 Chloramphenicol, CHL = 8 2 16 1 MIC x
30 Ciprofloxacin, CIP <= 1 1 MIC x
30 Erythromycin, ERY <= 0.25 1 1 MIC x
30 Gentamicin, GEN <= 2 1 1 MIC x
30 Penicillin, PEN = 0.25 2 1 MIC x
30 Streptomycin, STR <= 1000 0 256 0 MIC x
30 Tetracycline, TET <= 2 1 1 MIC x
31 Cefoxitin, FOX <= 4 1 4 1 MIC x
31 Chloramphenicol, CHL <= 16 2 16 1 MIC x
31 Ciprofloxacin, CIP <= 0.12 1 MIC x
31 Erythromycin, ERY <= 0.5 1 1 MIC x
31 Florfenicol, FFN <= 8 2 8 1 MIC x
31 Gentamicin, GEN <= 2 1 1 MIC x
31 Penicillin, PEN = 0.5 2 1 MIC x
31 Streptomycin, STR <= 16 0 256 0 MIC x
31 Sulfisoxazole, FIS <= 128 32 128 1 MIC x
31 Tetracycline, TET <= 1 1 1 MIC x
31 Trimethoprim, TMP <= 2 1 4 1 MIC x
33 Cefoxitin, FOX = 4 1 4 1 MIC x
33 Chloramphenicol, CHL = 8 2 16 1 MIC x
33 Ciprofloxacin, CIP = 0.25 1 MIC x
33 Erythromycin, ERY = 0.5 1 1 MIC x
33 Gentamicin, GEN = 1 1 1 MIC x
33 Penicillin, PEN = 0.25 2 1 MIC x
33 Tetracycline, TET <= 0.5 1 1 MIC x
33 Trimethoprim, TMP = 4 1 4 1 MIC x
34 Cefoxitin, FOX = 4 1 4 1 MIC x
34 Chloramphenicol, CHL = 16 2 16 1 MIC x
34 Ciprofloxacin, CIP = 0.5 1 MIC x
34 Erythromycin, ERY = 0.5 1 1 MIC x
34 Gentamicin, GEN <= 1 1 1 MIC x
34 Penicillin, PEN = 1 2 1 MIC x
34 Streptomycin, STR = 8 0 256 0 MIC x
34 Sulfisoxazole, FIS = 128 32 128 1 MIC x
34 Tetracycline, TET = 1 1 1 MIC x
34 Trimethoprim, TMP <= 2 1 4 1 MIC x
36 Cefoxitin, FOX = 25 1 4 0 MIC x
36 Chloramphenicol, CHL = 8 2 16 1 MIC x
36 Ciprofloxacin, CIP = 0.25 1 MIC x
36 Erythromycin, ERY = 0.5 1 1 MIC x
36 Gentamicin, GEN <= 0.5 1 1 MIC x
36 Penicillin, PEN = 0.5 2 1 MIC x
36 Tetracycline, TET <= 0.5 1 1 MIC x
36 Trimethoprim, TMP = 4 1 4 1 MIC x
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37 Cefoxitin, FOX = 4 1 4 1 AGA x
37 Chloramphenicol, CHL = 4 2 16 1 AGA x
37 Ciprofloxacin, CIP = 0.25 1 AGA x
37 Erythromycin, ERY = 0.25 1 1 AGA x
37 Gentamicin, GEN = 0.5 1 1 AGA x
37 Penicillin, PEN = 0.25 2 1 AGA x
37 Streptomycin, STR = 4 0 256 0 AGA x
37 Tetracycline, TET = 0.5 1 1 AGA x
37 Trimethoprim, TMP = 1 1 4 1 AGA x
39 Chloramphenicol, CHL = 2 2 16 1 MIC x
39 Ciprofloxacin, CIP = 0.5 1 MIC x
39 Erythromycin, ERY = 1 1 1 MIC x
39 Gentamicin, GEN = 1 1 1 MIC x
39 Penicillin, PEN = 2 2 1 MIC x
39 Tetracycline, TET = 1 1 1 MIC x
39 Trimethoprim, TMP = 1 1 4 1 MIC x
40 Cefoxitin, FOX = 2 1 4 1 MIC x
40 Chloramphenicol, CHL = 4 2 16 1 MIC x
40 Ciprofloxacin, CIP = 0.25 1 MIC x
40 Erythromycin, ERY = 0.25 1 1 MIC x
40 Gentamicin, GEN = 1 1 1 MIC x
40 Penicillin, PEN = 2 2 1 MIC x
40 Sulfisoxazole, FIS = 128 32 128 1 MIC x
40 Tetracycline, TET = 0.5 1 1 MIC x
40 Trimethoprim, TMP = 4 1 4 1 MIC x
42 Chloramphenicol, CHL = 8 2 16 1 MIC x
42 Ciprofloxacin, CIP <= 0.25 1 MIC x
42 Erythromycin, ERY = 0.5 1 1 MIC x
42 Gentamicin, GEN <= 1 1 1 MIC x
42 Penicillin, PEN = 0.5 2 1 MIC x
42 Streptomycin, STR = 8 0 256 0 MIC x
42 Sulfisoxazole, FIS <= 64 32 128 1 MIC x
42 Tetracycline, TET <= 0.5 1 1 MIC x
42 Trimethoprim, TMP <= 2 1 4 1 MIC x
56 Cefoxitin, FOX = 30 23 29 0 DD x
56 Chloramphenicol, CHL = 23 16 26 1 DD x
56 Ciprofloxacin, CIP = 26 22 30 1 DD x
56 Erythromycin, ERY = 27 22 30 1 DD x
56 Florfenicol, FFN = 24 0 256 0 DD x
56 Gentamicin, GEN = 26 19 27 1 DD x
56 Penicillin, PEN = 34 26 37 1 DD x
56 Streptomycin, STR = 18 14 22 1 DD x
56 Sulfisoxazole, FIS = 24 24 30 1 DD x
56 Tetracycline, TET = 28 24 34 1 DD x
56 Trimethoprim, TMP = 20 19 26 1 DD x
57 Cefoxitin, FOX = 29 23 29 1 DD x
57 Chloramphenicol, CHL = 26 16 26 1 DD x
57 Ciprofloxacin, CIP = 29 22 30 1 DD x
57 Erythromycin, ERY = 30 22 30 1 DD x
57 Florfenicol, FFN = 27 0 256 0 DD x
57 Gentamicin, GEN = 27 19 27 1 DD x
57 Penicillin, PEN = 33 26 37 1 DD x
57 Streptomycin, STR = 22 14 22 1 DD x
57 Sulfisoxazole, FIS = 30 24 30 1 DD x
57 Tetracycline, TET = 27 24 34 1 DD x
57 Trimethoprim, TMP = 26 19 26 1 DD x
58 Cefoxitin, FOX = 4 1 4 1 MIC x
58 Chloramphenicol, CHL = 8 2 16 1 MIC x
58 Ciprofloxacin, CIP = 0.5 1 MIC x
58 Erythromycin, ERY = 0.5 1 1 MIC x
58 Gentamicin, GEN <= 1 1 1 MIC x
58 Penicillin, PEN = 0.25 2 1 MIC x
58 Streptomycin, STR = 8 0 256 0 MIC x
58 Tetracycline, TET <= 0.5 1 1 MIC x
58 Trimethoprim, TMP = 4 1 4 1 MIC x
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Test results from reference strain Escherichia coli ATCC 25922
Lab no Antib Operator Value Low limit High limit Mark Method
1 Ampicillin, AMP = 4 2 8 1 MIC
1 Cefotaxime, CTX <= 0.125 1 MIC
1 Ceftiofur, XNL <= 0.5 1 1 MIC
1 Chloramphenicol, CHL = 4 2 8 1 MIC
1 Ciprofloxacin, CIP <= 0.015 1 MIC
1 Gentamicin, GEN = 1 1 1 MIC
1 Nalidixic acid, NAL <= 4 1 4 1 MIC
1 Streptomycin, STR <= 8 4 16 1 MIC
1 Tetracycline, TET <= 2 2 1 MIC
1 Trimethoprim, TMP <= 1 2 1 MIC
2 Ampicillin, AMP = 4 2 8 1 MIC
2 Cefotaxime, CTX <= 0.06 1 MIC
2 Ceftazidime, CAZ = 0.25 1 MIC
2 Chloramphenicol, CHL = 8 2 8 1 MIC
2 Ciprofloxacin, CIP = 0.016 1 MIC
2 Gentamicin, GEN = 0.5 1 1 MIC
2 Nalidixic acid, NAL <= 2 1 4 1 MIC
2 Streptomycin, STR <= 4 4 16 1 MIC
2 Tetracycline, TET <= 1 2 1 MIC
2 Trimethoprim, TMP = 0.5 2 1 MIC
4 Ampicillin, AMP = 8 2 8 1 MIC
4 Cefotaxime, CTX = 0.06 1 MIC
4 Ceftazidime, CAZ = 0.25 1 MIC
4 Chloramphenicol, CHL = 4 2 8 1 MIC
4 Ciprofloxacin, CIP = 0.015 1 MIC
4 Gentamicin, GEN = 4 1 0 MIC
4 Imipenem, IMI = 0.5 0 MIC
4 Nalidixic acid, NAL = 4 1 4 1 MIC
4 Streptomycin, STR = 8 4 16 1 MIC
4 Tetracycline, TET = 1 2 1 MIC
4 Trimethoprim, TMP = 1 2 1 MIC
6 Ampicillin, AMP = 2 2 8 1 MIC
6 Cefotaxime, CTX < 0.06 1 MIC
6 Ceftazidime, CAZ < 0.25 1 MIC
6 Chloramphenicol, CHL = 2 2 8 1 MIC
6 Ciprofloxacin, CIP < 0.008 1 MIC
6 Gentamicin, GEN = 0.5 1 1 MIC
6 Nalidixic acid, NAL < 4 1 4 1 MIC
6 Streptomycin, STR = 8 4 16 1 MIC
6 Tetracycline, TET < 1 2 1 MIC
6 Trimethoprim, TMP = 0.5 2 1 MIC
9 Ampicillin, AMP = 4 2 8 1 MIC
9 Cefotaxime, CTX = 0.12 1 MIC
9 Cefoxitin, FOX = 4 2 8 1 MIC
9 Ceftazidime, CAZ = 0.25 1 MIC
9 Ceftiofur, XNL = 0.25 1 1 MIC
9 Chloramphenicol, CHL = 4 2 8 1 MIC
9 Ciprofloxacin, CIP = 0.008 1 MIC
9 Gentamicin, GEN = 0.5 1 1 MIC
9 Imipenem, IMI = 0.12 1 MIC
9 Nalidixic acid, NAL = 4 1 4 1 MIC
9 Streptomycin, STR = 8 4 16 1 MIC
9 Sulfisoxazole, FIS = 16 8 32 1 MIC
9 Tetracycline, TET = 1 2 1 MIC
9 Trimethoprim, TMP = 1 2 1 MIC
Appendix 6c, page 2 of 6
Lab no Antib Operator Value Low limit High limit Mark Method
11 Ampicillin, AMP = 4 2 8 1 MIC
11 Cefotaxime, CTX = 0.06 1 MIC
11 Ceftazidime, CAZ = 0.5 1 MIC
11 Chloramphenicol, CHL = 4 2 8 1 MIC
11 Ciprofloxacin, CIP = 0.03 0 MIC
11 Gentamicin, GEN = 1 1 1 MIC
11 Nalidixic acid, NAL = 2 1 4 1 MIC
11 Streptomycin, STR = 4 4 16 1 MIC
11 Sulfisoxazole, FIS = 16 8 32 1 MIC
11 Tetracycline, TET <= 1 2 1 MIC
11 Trimethoprim, TMP = 0.5 2 1 MIC
12 Ampicillin, AMP = 2 2 8 1 MIC
12 Cefotaxime, CTX = 0.12 1 MIC
12 Cefoxitin, FOX = 4 2 8 1 MIC
12 Ceftazidime, CAZ = 0.5 1 MIC
12 Chloramphenicol, CHL = 4 2 8 1 MIC
12 Ciprofloxacin, CIP = 0.03 0 MIC
12 Gentamicin, GEN = 2 1 0 MIC
12 Nalidixic acid, NAL = 2 1 4 1 MIC
12 Streptomycin, STR = 16 4 16 1 MIC
12 Tetracycline, TET <= 1 2 1 MIC
12 Trimethoprim, TMP = 0.5 2 1 MIC
14 Cefotaxime, CTX = 36 29 35 0 DD
14 Cefoxitin, FOX = 28 23 29 1 DD
14 Ceftazidime, CAZ = 32 25 32 1 DD
14 Ceftiofur, XNL = 31 26 31 1 DD
14 Ciprofloxacin, CIP = 37 30 40 1 DD
14 Gentamicin, GEN = 26 19 26 1 DD
14 Nalidixic acid, NAL = 28 22 28 1 DD
14 Tetracycline, TET = 26 18 25 0 DD
15 Cefotaxime, CTX = 35 29 35 1 DD
15 Cefoxitin, FOX = 28 23 29 1 DD
15 Ceftazidime, CAZ = 32 25 32 1 DD
15 Ceftiofur, XNL = 31 26 31 1 DD
15 Chloramphenicol, CHL = 26 21 27 1 DD
15 Gentamicin, GEN = 26 19 26 1 DD
15 Nalidixic acid, NAL = 25 22 28 1 DD
15 Streptomycin, STR = 19 12 20 1 DD
15 Tetracycline, TET = 25 18 25 1 DD
15 Trimethoprim, TMP = 25 21 28 1 DD
16 Ampicillin, AMP = 4 2 8 1 MIC
16 Cefotaxime, CTX = 0.12 1 MIC
16 Ceftazidime, CAZ = 0.25 1 MIC
16 Chloramphenicol, CHL = 8 2 8 1 MIC
16 Ciprofloxacin, CIP = 0.015 1 MIC
16 Gentamicin, GEN = 0.5 1 1 MIC
16 Nalidixic acid, NAL = 2 1 4 1 MIC
16 Streptomycin, STR = 8 4 16 1 MIC
16 Sulfisoxazole, FIS = 32 8 32 1 MIC
16 Tetracycline, TET <= 1 2 1 MIC
16 Trimethoprim, TMP = 2 2 1 MIC
17 Ampicillin, AMP = 2 2 8 1 MIC
17 Cefotaxime, CTX <= 0.06 1 MIC
17 Cefoxitin, FOX = 4 2 8 1 MIC
17 Ceftazidime, CAZ <= 0.25 1 MIC
17 Chloramphenicol, CHL = 4 2 8 1 MIC
17 Ciprofloxacin, CIP = 0.015 1 MIC
17 Gentamicin, GEN = 0.5 1 1 MIC
17 Nalidixic acid, NAL <= 4 1 4 1 MIC
17 Streptomycin, STR = 4 4 16 1 MIC
17 Sulfisoxazole, FIS = 32 8 32 1 MIC
17 Tetracycline, TET <= 1 2 1 MIC
17 Trimethoprim, TMP = 1 2 1 MIC
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18 Ampicillin, AMP = 4 2 8 1 MIC
18 Cefotaxime, CTX = 0.06 1 MIC
18 Ceftazidime, CAZ <= 0.25 1 MIC
18 Chloramphenicol, CHL = 2 2 8 1 MIC
18 Ciprofloxacin, CIP = 0.008 1 MIC
18 Gentamicin, GEN = 0.5 1 1 MIC
18 Nalidixic acid, NAL <= 4 1 4 1 MIC
18 Streptomycin, STR = 4 4 16 1 MIC
18 Sulfisoxazole, FIS = 32 8 32 1 MIC
18 Tetracycline, TET <= 1 2 1 MIC
18 Trimethoprim, TMP = 1 2 1 MIC
19 Ampicillin, AMP = 4 2 8 1 MIC
19 Cefotaxime, CTX = 0.06 1 MIC
19 Ceftazidime, CAZ = 0.25 1 MIC
19 Chloramphenicol, CHL = 4 2 8 1 MIC
19 Ciprofloxacin, CIP = 0.015 1 MIC
19 Gentamicin, GEN = 0.5 1 1 MIC
19 Nalidixic acid, NAL = 4 1 4 1 MIC
19 Streptomycin, STR = 4 4 16 1 MIC
19 Sulfisoxazole, FIS = 32 8 32 1 MIC
19 Tetracycline, TET = 1 2 1 MIC
19 Trimethoprim, TMP = 0.5 2 1 MIC
20 Ampicillin, AMP = 4 2 8 1 MIC
20 Cefotaxime, CTX <= 0.06 1 MIC
20 Ceftazidime, CAZ <= 0.25 1 MIC
20 Chloramphenicol, CHL = 4 2 8 1 MIC
20 Ciprofloxacin, CIP <= 0.008 1 MIC
20 Gentamicin, GEN = 0.5 1 1 MIC
20 Nalidixic acid, NAL <= 4 1 4 1 MIC
20 Streptomycin, STR = 4 4 16 1 MIC
20 Sulfisoxazole, FIS = 32 8 32 1 MIC
20 Tetracycline, TET = 2 2 1 MIC
20 Trimethoprim, TMP <= 0.5 2 1 MIC
21 Ampicillin, AMP = 2 2 8 1 MIC
21 Cefotaxime, CTX = 0.12 1 MIC
21 Ceftazidime, CAZ = 0.5 1 MIC
21 Chloramphenicol, CHL = 2 2 8 1 MIC
21 Ciprofloxacin, CIP = 0.015 1 MIC
21 Gentamicin, GEN = 0.5 1 1 MIC
21 Nalidixic acid, NAL = 4 1 4 1 MIC
21 Sulfisoxazole, FIS = 8 8 32 1 MIC
21 Tetracycline, TET = 1 2 1 MIC
21 Trimethoprim, TMP = 1 2 1 MIC
22 Ampicillin, AMP = 8 2 8 1 MIC
22 Cefotaxime, CTX < 0.06 1 MIC
22 Ceftazidime, CAZ < 0.25 1 MIC
22 Chloramphenicol, CHL = 4 2 8 1 MIC
22 Ciprofloxacin, CIP = 0.015 1 MIC
22 Gentamicin, GEN = 0.5 1 1 MIC
22 Nalidixic acid, NAL < 4 1 4 1 MIC
22 Streptomycin, STR = 4 4 16 1 MIC
22 Sulfisoxazole, FIS = 32 8 32 1 MIC
22 Tetracycline, TET = 2 2 1 MIC
22 Trimethoprim, TMP = 1 2 1 MIC
23 Ampicillin, AMP = 1 2 8 0 MIC
23 Cefotaxime, CTX = 0.06 1 MIC
23 Cefoxitin, FOX < 4 2 8 1 MIC
23 Ceftazidime, CAZ < 0.25 1 MIC
23 Chloramphenicol, CHL = 4 2 8 1 MIC
23 Ciprofloxacin, CIP < 0.008 1 MIC
23 Gentamicin, GEN = 0.5 1 1 MIC
23 Nalidixic acid, NAL = 4 1 4 1 MIC
23 Streptomycin, STR = 4 4 16 1 MIC
23 Sulfisoxazole, FIS = 32 8 32 1 MIC
23 Tetracycline, TET < 1 2 1 MIC
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25 Ampicillin, AMP = 4 2 8 1 MIC
25 Cefotaxime, CTX <= 0.06 1 MIC
25 Ceftazidime, CAZ <= 0.25 1 MIC
25 Chloramphenicol, CHL = 4 2 8 1 MIC
25 Ciprofloxacin, CIP = 0.015 1 MIC
25 Gentamicin, GEN = 1 1 1 MIC
25 Nalidixic acid, NAL <= 4 1 4 1 MIC
25 Streptomycin, STR = 8 4 16 1 MIC
25 Sulfisoxazole, FIS <= 8 8 32 1 MIC
25 Tetracycline, TET <= 1 2 1 MIC
25 Trimethoprim, TMP <= 0.5 2 1 MIC
26 Ampicillin, AMP = 4 2 8 1 MIC
26 Cefotaxime, CTX = 0.12 1 MIC
26 Ceftazidime, CAZ <= 0.25 1 MIC
26 Chloramphenicol, CHL = 4 2 8 1 MIC
26 Ciprofloxacin, CIP = 0.015 1 MIC
26 Gentamicin, GEN = 0.5 1 1 MIC
26 Nalidixic acid, NAL <= 4 1 4 1 MIC
26 Streptomycin, STR = 8 4 16 1 MIC
26 Tetracycline, TET <= 1 2 1 MIC
26 Trimethoprim, TMP <= 0.5 2 1 MIC
29 Ampicillin, AMP = 8 2 8 1 MIC
29 Cefotaxime, CTX = 0.12 1 MIC
29 Ceftazidime, CAZ = 0.5 1 MIC
29 Chloramphenicol, CHL = 8 2 8 1 MIC
29 Ciprofloxacin, CIP = 0.016 1 MIC
29 Gentamicin, GEN = 0.5 1 1 MIC
29 Nalidixic acid, NAL = 4 1 4 1 MIC
29 Streptomycin, STR = 4 4 16 1 MIC
29 Tetracycline, TET = 2 2 1 MIC
29 Trimethoprim, TMP = 1 2 1 MIC
30 Ampicillin, AMP = 4 2 8 1 MIC
30 Cefotaxime, CTX <= 0.06 1 MIC
30 Cefoxitin, FOX <= 4 2 8 1 MIC
30 Ceftazidime, CAZ <= 0.25 1 MIC
30 Chloramphenicol, CHL = 4 2 8 1 MIC
30 Ciprofloxacin, CIP <= 0.008 1 MIC
30 Gentamicin, GEN = 1 1 1 MIC
30 Imipenem, IMI <= 0.5 1 MIC
30 Nalidixic acid, NAL <= 4 1 4 1 MIC
30 Streptomycin, STR = 4 4 16 1 MIC
30 Sulfisoxazole, FIS = 32 8 32 1 MIC
30 Tetracycline, TET <= 1 2 1 MIC
30 Trimethoprim, TMP <= 0.5 2 1 MIC
32 Ampicillin, AMP = 4 2 8 1 MIC
32 Cefotaxime, CTX <= 0.06 1 MIC
32 Ceftazidime, CAZ <= 0.25 1 MIC
32 Chloramphenicol, CHL = 4 2 8 1 MIC
32 Ciprofloxacin, CIP <= 0.008 1 MIC
32 Gentamicin, GEN = 0.5 1 1 MIC
32 Nalidixic acid, NAL <= 4 1 4 1 MIC
32 Streptomycin, STR = 8 4 16 1 MIC
32 Sulfisoxazole, FIS = 16 8 32 1 MIC
32 Tetracycline, TET <= 1 2 1 MIC
32 Trimethoprim, TMP <= 0.5 2 1 MIC
33 Ampicillin, AMP = 4 2 8 1 MIC
33 Cefotaxime, CTX = 0.12 1 MIC
33 Cefoxitin, FOX = 4 2 8 1 MIC
33 Chloramphenicol, CHL = 4 2 8 1 MIC
33 Ciprofloxacin, CIP = 0.06 0 MIC
33 Gentamicin, GEN = 0.5 1 1 MIC
33 Nalidixic acid, NAL = 4 1 4 1 MIC
33 Streptomycin, STR = 4 4 16 1 MIC
33 Sulfisoxazole, FIS = 32 8 32 1 MIC
33 Tetracycline, TET = 2 2 1 MIC
33 Trimethoprim, TMP = 1 2 1 MIC
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34 Ampicillin, AMP = 4 2 8 1 MIC
34 Cefotaxime, CTX = 0.12 1 MIC
34 Ceftazidime, CAZ <= 0.25 1 MIC
34 Chloramphenicol, CHL = 4 2 8 1 MIC
34 Ciprofloxacin, CIP = 0.015 1 MIC
34 Gentamicin, GEN = 1 1 1 MIC
34 Nalidixic acid, NAL <= 4 1 4 1 MIC
34 Streptomycin, STR = 4 4 16 1 MIC
34 Sulfisoxazole, FIS = 32 8 32 1 MIC
34 Tetracycline, TET <= 1 2 1 MIC
34 Trimethoprim, TMP = 1 2 1 MIC
36 Ampicillin, AMP = 4 2 8 1 MIC
36 Cefotaxime, CTX = 0.12 1 MIC
36 Ceftazidime, CAZ = 1 0 MIC
36 Chloramphenicol, CHL = 4 2 8 1 MIC
36 Ciprofloxacin, CIP = 0.03 0 MIC
36 Gentamicin, GEN = 0.5 1 1 MIC
36 Nalidixic acid, NAL = 4 1 4 1 MIC
36 Streptomycin, STR = 4 4 16 1 MIC
36 Sulfisoxazole, FIS = 32 8 32 1 MIC
36 Tetracycline, TET = 2 2 1 MIC
36 Trimethoprim, TMP = 1 2 1 MIC
37 Ampicillin, AMP = 4 2 8 1 AGA
37 Cefotaxime, CTX <= 0.06 1 AGA
37 Chloramphenicol, CHL = 4 2 8 1 AGA
37 Ciprofloxacin, CIP <= 0.008 1 AGA
37 Gentamicin, GEN = 0.5 1 1 AGA
37 Nalidixic acid, NAL = 4 1 4 1 AGA
37 Streptomycin, STR = 4 4 16 1 AGA
37 Tetracycline, TET = 2 2 1 AGA
37 Trimethoprim, TMP = 0.5 2 1 AGA
39 Ampicillin, AMP = 4 2 8 1 MIC
39 Cefotaxime, CTX = 0.12 1 MIC
39 Ceftazidime, CAZ = 0.5 1 MIC
39 Chloramphenicol, CHL = 2 2 8 1 MIC
39 Ciprofloxacin, CIP = 0.016 1 MIC
39 Gentamicin, GEN = 0.5 1 1 MIC
39 Nalidixic acid, NAL = 4 1 4 1 MIC
39 Streptomycin, STR = 16 4 16 1 MIC
39 Tetracycline, TET = 2 2 1 MIC
39 Trimethoprim, TMP = 2 2 1 MIC
40 Ampicillin, AMP = 8 2 8 1 MIC
40 Cefotaxime, CTX = 0.25 0 MIC
40 Cefoxitin, FOX = 8 2 8 1 MIC
40 Ceftazidime, CAZ = 0.5 1 MIC
40 Ceftiofur, XNL = 1 1 1 MIC
40 Chloramphenicol, CHL = 16 2 8 0 MIC
40 Ciprofloxacin, CIP = 0.03 0 MIC
40 Gentamicin, GEN = 2 1 0 MIC
40 Nalidixic acid, NAL = 16 1 4 0 MIC
40 Streptomycin, STR = 8 4 16 1 MIC
40 Sulfisoxazole, FIS = 256 8 32 0 MIC
40 Tetracycline, TET = 8 2 0 MIC
40 Trimethoprim, TMP = 2 2 1 MIC
42 Ampicillin, AMP = 8 2 8 1 MIC
42 Cefotaxime, CTX = 0.12 1 MIC
42 Cefoxitin, FOX <= 4 2 8 1 MIC
42 Ceftazidime, CAZ <= 0.25 1 MIC
42 Chloramphenicol, CHL = 8 2 8 1 MIC
42 Ciprofloxacin, CIP = 0.015 1 MIC
42 Gentamicin, GEN = 1 1 1 MIC
42 Imipenem, IMI <= 0.5 1 MIC
42 Nalidixic acid, NAL <= 4 1 4 1 MIC
42 Streptomycin, STR = 4 4 16 1 MIC
42 Sulfisoxazole, FIS = 32 8 32 1 MIC
42 Tetracycline, TET <= 1 2 1 MIC
42 Trimethoprim, TMP = 1 2 1 MIC
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57 Ampicillin, AMP = 21 16 22 1 DD
57 Cefotaxime, CTX = 32 29 35 1 DD
57 Cefoxitin, FOX = 28 23 29 1 DD
57 Ceftazidime, CAZ = 26 25 32 1 DD
57 Ceftiofur, XNL = 23 26 31 0 DD
57 Chloramphenicol, CHL = 32 21 27 0 DD
57 Ciprofloxacin, CIP = 25 30 40 0 DD
57 Gentamicin, GEN = 23 19 26 1 DD
57 Nalidixic acid, NAL = 27 22 28 1 DD
57 Streptomycin, STR = 20 12 20 1 DD
57 Sulfisoxazole, FIS = 24 15 23 0 DD
57 Tetracycline, TET = 23 18 25 1 DD
57 Trimethoprim, TMP = 27 21 28 1 DD
58 Ampicillin, AMP = 8 2 8 1 MIC
58 Cefotaxime, CTX <= 0.06 1 MIC
58 Cefoxitin, FOX = 4 2 8 1 MIC
58 Ceftazidime, CAZ <= 0.25 1 MIC
58 Ceftiofur, XNL = 0.5 1 1 MIC
58 Chloramphenicol, CHL = 4 2 8 1 MIC
58 Ciprofloxacin, CIP = 0.015 1 MIC
58 Gentamicin, GEN = 1 1 1 MIC
58 Imipenem, IMI <= 0.5 1 MIC
58 Nalidixic acid, NAL <= 4 1 4 1 MIC
58 Streptomycin, STR = 8 4 16 1 MIC
58 Sulfisoxazole, FIS = 32 8 32 1 MIC
58 Tetracycline, TET <= 1 2 1 MIC
58 Trimethoprim, TMP <= 0.5 2 1 MIC
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Appendix 7a - Summary of obtained results for the enterococci trial
Expected Number Number
result expected deviating
results results
EURL ENT 6.1 Ampicillin , AMP S 4 96 24 1
Chloramphenicol, CHL S 0 100 29 0
Ciprofloxacin , CIP S 4 96 23 1
Erythromycin, ERY S 24 76 22 7
Gentamicin, GEN S 4 96 25 1
Linezolid, LZD S 4 96 24 1
Quinu-dalfo-pristin, Q-D S 6 94 16 1
Streptomycin, STR S 8 92 24 2
Tetracycline, TET S 3 97 28 1
Vancomycin, VAN S 3 97 28 1
EURL ENT 6.2 Ampicillin , AMP S 16 84 21 4
Chloramphenicol, CHL S 3 97 28 1
Ciprofloxacin , CIP S 4 96 23 1
Erythromycin, ERY S 7 93 27 2
Gentamicin, GEN S 4 96 25 1
Linezolid, LZD S 4 96 24 1
Quinu-dalfo-pristin, Q-D S 0 100 17 0
Streptomycin, STR S 12 88 23 3
Tetracycline, TET R 100 0 29 0
Vancomycin, VAN R 100 0 29 0
EURL ENT 6.3 Ampicillin , AMP S 4 96 24 1
Chloramphenicol, CHL R 82 18 23 5
Ciprofloxacin , CIP S 4 96 23 1
Erythromycin, ERY R 100 0 29 0
Gentamicin, GEN R 100 0 29 0
Linezolid, LZD S 4 96 24 1
Quinu-dalfo-pristin, Q-D - 100 0 0 0
Streptomycin, STR R 97 3 28 1
Tetracycline, TET R 100 0 29 0
Vancomycin, VAN S 7 93 27 2
EURL ENT 6.4 Ampicillin , AMP S 4 96 24 1
Chloramphenicol, CHL S 3 97 28 1
Ciprofloxacin , CIP S 4 96 23 1
Erythromycin, ERY S 3 97 28 1
Gentamicin, GEN S 8 92 24 2
Linezolid, LZD S 4 96 24 1
Quinu-dalfo-pristin, Q-D - 100 0 0 0
Streptomycin, STR S 10 90 26 3
Tetracycline, TET S 3 97 28 1
Vancomycin, VAN S 7 93 27 2
EURL ENT 6.5 Ampicillin , AMP S 4 96 24 1
Chloramphenicol, CHL R 100 0 29 0
Ciprofloxacin , CIP S 4 96 23 1
Erythromycin, ERY S 3 97 28 1
Gentamicin, GEN S 8 92 24 2
Linezolid, LZD S 4 96 24 1
Quinu-dalfo-pristin, Q-D - 100 0 0 0
Streptomycin, STR R 83 17 24 5
Tetracycline, TET R 100 0 29 0
Vancomycin, VAN S 3 97 28 1
Strain Antimicrobial % R % S
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Expected Number Number
result expected deviating
results results
Strain Antimicrobial % R % S
EURL ENT 6.6 Ampicillin , AMP S 4 96 24 1
Chloramphenicol, CHL S 3 97 28 1
Ciprofloxacin , CIP S 4 96 23 1
Erythromycin, ERY R 100 0 29 0
Gentamicin, GEN S 4 96 25 1
Linezolid, LZD S 4 96 24 1
Quinu-dalfo-pristin, Q-D - 100 0 0 0
Streptomycin, STR R 97 3 28 1
Tetracycline, TET R 100 0 29 0
Vancomycin, VAN S 3 97 28 1
EURL ENT 6.7 Ampicillin , AMP S 0 100 25 0
Chloramphenicol, CHL S 3 97 28 1
Ciprofloxacin , CIP S 4 96 23 1
Erythromycin, ERY S 3 97 28 1
Gentamicin, GEN S 8 92 24 2
Linezolid, LZD S 4 96 24 1
Quinu-dalfo-pristin, Q-D - 100 0 0 0
Streptomycin, STR S 10 90 26 3
Tetracycline, TET R 97 3 28 1
Vancomycin, VAN S 3 97 28 1
EURL ENT 6.8 Ampicillin , AMP S 0 100 25 0
Chloramphenicol, CHL S 3 97 28 1
Ciprofloxacin , CIP S 4 96 23 1
Erythromycin, ERY R 100 0 29 0
Gentamicin, GEN S 8 92 24 2
Linezolid, LZD S 4 96 24 1
Quinu-dalfo-pristin, Q-D - 100 0 0 0
Streptomycin, STR S 14 86 24 4
Tetracycline, TET R 100 0 29 0
Vancomycin, VAN S 3 97 28 1
Appendix 7b, page 1 of 2 
Appendix 7b - Summary of obtained results for the staphylococci trial
Expected Number Number
result expected deviating
results results
EURL ST 6.1 Cefoxitin, FOX R 100 0 29 0
Chloramphenicol, CHL S 0 100 32 0
Erythromycin, ERY R 100 0 34 0
Florfenicol, FFN S 0 100 12 0
Gentamicin, GEN S 3 97 32 1
Penicillin, PEN R 100 0 33 0
Streptomycin, STR S 8 92 24 2
Sulfamethoxazole, SMX S 4 96 24 1
Tetracycline, TET R 100 0 34 0
Trimethoprim, TMP S 0 100 29 0
EURL ST 6.2 Cefoxitin, FOX S 0 100 29 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 0 100 32 0
Erythromycin, ERY S 0 100 34 0
Florfenicol, FFN S 0 100 12 0
Gentamicin, GEN S 3 97 32 1
Penicillin, PEN R 100 0 33 0
Streptomycin, STR S 12 88 23 3
Sulfamethoxazole, SMX S 16 84 21 4
Tetracycline, TET S 0 100 34 0
Trimethoprim, TMP S 21 79 23 6
EURL ST 6.3 Cefoxitin, FOX S 0 100 29 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 3 97 31 1
Erythromycin, ERY S 0 100 34 0
Florfenicol, FFN S 0 100 12 0
Gentamicin, GEN S 3 97 32 1
Penicillin, PEN R 100 0 32 0
Streptomycin, STR S 4 96 25 1
Sulfamethoxazole, SMX S 12 88 23 3
Tetracycline, TET S 0 100 34 0
Trimethoprim, TMP S 14 86 25 4
EURL ST 6.4 Cefoxitin, FOX S 0 100 29 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 0 100 32 0
Erythromycin, ERY S 0 100 34 0
Florfenicol, FFN S 0 100 12 0
Gentamicin, GEN S 3 97 32 1
Penicillin, PEN R 100 0 33 0
Streptomycin, STR S 4 96 25 1
Sulfamethoxazole, SMX S 0 100 24 0
Tetracycline, TET R 97 3 33 1
Trimethoprim, TMP S 0 100 29 0
EURL ST 6.5 Cefoxitin, FOX S 0 100 29 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 0 100 32 0
Erythromycin, ERY S 0 100 34 0
Florfenicol, FFN S 0 100 12 0
Gentamicin, GEN S 3 97 32 1
Penicillin, PEN R 100 0 33 0
Streptomycin, STR R 100 0 26 0
Sulfamethoxazole, SMX S 8 92 24 2
Tetracycline, TET R 97 3 33 1
Trimethoprim, TMP S 0 100 29 0
Strain Antimicrobial % R % S
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EURL ST 6.6 Cefoxitin, FOX R 97 3 28 1
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 0 100 32 0
Erythromycin, ERY S 3 97 33 1
Florfenicol, FFN S 0 100 12 0
Gentamicin, GEN S 0 100 33 0
Penicillin, PEN R 97 3 32 1
Streptomycin, STR R 100 0 26 0
Sulfamethoxazole, SMX S 0 100 26 0
Tetracycline, TET R 97 3 33 1
Trimethoprim, TMP R 100 0 29 0
EURL ST 6.7 Cefoxitin, FOX R 100 0 29 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 0 100 32 0
Erythromycin, ERY S 3 97 33 1
Florfenicol, FFN S 0 100 12 0
Gentamicin, GEN S 3 97 32 1
Penicillin, PEN R 100 0 33 0
Streptomycin, STR S 12 88 23 3
Sulfamethoxazole, SMX S 0 100 25 0
Tetracycline, TET R 100 0 34 0
Trimethoprim, TMP S 3 97 28 1
EURL ST 6.8 Cefoxitin, FOX R 100 0 29 0
Chloramphenicol, CHL S 0 100 32 0
Erythromycin, ERY S 0 100 34 0
Florfenicol, FFN S 0 100 12 0
Gentamicin, GEN R 97 3 32 1
Penicillin, PEN R 100 0 33 0
Streptomycin, STR R 100 0 26 0
Sulfamethoxazole, SMX R 88 12 22 3
Tetracycline, TET R 100 0 34 0
Trimethoprim, TMP S 0 100 29 0
Appendix 7c, page 1 of 3 
Appendix 7c - Summary of obtained results for the E.coli trial
Expected Number Number
result expected deviating
results results
EURL EC 6.1 Ampicillin, AMP R 100 0 31 0
Cefotaxime, CTX R 100 0 33 0
Ceftazidime, CAZ R 100 0 31 0
Ceftiofur, XNL R 86 14 6 1
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 0 100 32 0
Florfenicol, FFN S 0 100 26 0
Gentamicin, GEN S 3 97 32 1
Nalidixic acid, NAL S 0 100 33 0
Streptomycin, STR S 13 87 27 4
Sulfamethoxazole, SMX S 3 97 29 1
Tetracycline, TET S 3 97 32 1
Trimethoprim, TMP S 0 100 31 0
EURL EC 6.2 Ampicillin, AMP S 10 90 28 3
Cefotaxime, CTX S 3 97 32 1
Ceftazidime, CAZ S 3 97 29 1
Ceftiofur, XNL S 0 100 8 0
Chloramphenicol, CHL S 0 100 31 0
Ciprofloxacin, CIP R 94 6 30 2
Florfenicol, FFN S 0 100 26 0
Gentamicin, GEN S 3 97 32 1
Nalidixic acid, NAL R 100 0 33 0
Streptomycin, STR S 6 94 30 2
Sulfamethoxazole, SMX S 7 93 28 2
Tetracycline, TET R 100 0 33 0
Trimethoprim, TMP S 0 100 31 0
EURL EC 6.3 Ampicillin, AMP R 100 0 31 0
Cefotaxime, CTX S 3 97 32 1
Ceftazidime, CAZ S 3 97 29 1
Ceftiofur, XNL S 0 100 7 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 3 97 31 1
Florfenicol, FFN S 0 100 26 0
Gentamicin, GEN S 3 97 32 1
Nalidixic acid, NAL S 0 100 33 0
Streptomycin, STR R 100 0 32 0
Sulfamethoxazole, SMX R 100 0 30 0
Tetracycline, TET R 100 0 33 0
Trimethoprim, TMP R 100 0 31 0
Strain Antimicrobial % R % S
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Expected Number Number
result expected deviating
results results
Strain Antimicrobial % R % S
EURL EC 6.4 Ampicillin, AMP R 100 0 31 0
Cefotaxime, CTX R 100 0 33 0
Ceftazidime, CAZ R 97 3 30 1
Ceftiofur, XNL R 100 0 7 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 0 100 32 0
Florfenicol, FFN S 0 100 26 0
Gentamicin, GEN S 0 100 33 0
Nalidixic acid, NAL S 0 100 33 0
Streptomycin, STR S 3 97 31 1
Sulfamethoxazole, SMX S 0 100 30 0
Tetracycline, TET S 0 100 33 0
Trimethoprim, TMP S 0 100 30 0
EURL EC 6.5 Ampicillin, AMP S 0 100 31 0
Cefotaxime, CTX S 0 100 33 0
Ceftazidime, CAZ S 3 97 29 1
Ceftiofur, XNL S 0 100 7 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP R 100 0 32 0
Florfenicol, FFN S 0 100 26 0
Gentamicin, GEN S 3 97 32 1
Nalidixic acid, NAL R 100 0 33 0
Streptomycin, STR R 97 3 31 1
Sulfamethoxazole, SMX R 100 0 30 0
Tetracycline, TET S 0 100 33 0
Trimethoprim, TMP S 0 100 31 0
EURL EC 6.6 Ampicillin, AMP S 3 97 30 1
Cefotaxime, CTX S 0 100 33 0
Ceftazidime, CAZ S 3 97 29 1
Ceftiofur, XNL S 0 100 7 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 0 100 32 0
Florfenicol, FFN S 0 100 26 0
Gentamicin, GEN S 3 97 32 1
Nalidixic acid, NAL S 0 100 33 0
Streptomycin, STR S 6 94 30 2
Sulfamethoxazole, SMX S 3 97 29 1
Tetracycline, TET S 3 97 32 1
Trimethoprim, TMP S 0 100 31 0
EURL EC 6.7 Ampicillin, AMP R 100 0 31 0
Cefotaxime, CTX R 100 0 33 0
Ceftazidime, CAZ R 86 14 25 4
Ceftiofur, XNL R 100 0 7 0
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP R 100 0 32 0
Florfenicol, FFN S 0 100 26 0
Gentamicin, GEN R 97 3 32 1
Nalidixic acid, NAL R 100 0 33 0
Sulfamethoxazole, SMX R 100 0 30 0
Tetracycline, TET R 100 0 33 0
Trimethoprim, TMP R 100 0 31 0
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Expected Number Number
result expected deviating
results results
Strain Antimicrobial % R % S
EURL EC 6.8 Ampicillin, AMP R 100 0 31 0
Cefotaxime, CTX R 97 3 32 1
Ceftazidime, CAZ R 100 0 31 0
Ceftiofur, XNL R 86 14 6 1
Chloramphenicol, CHL S 0 100 32 0
Ciprofloxacin, CIP S 3 97 31 1
Florfenicol, FFN S 0 100 26 0
Gentamicin, GEN S 3 97 32 1
Nalidixic acid, NAL S 0 100 33 0
Streptomycin, STR S 9 91 29 3
Sulfamethoxazole, SMX S 3 97 29 1
Tetracycline, TET S 0 100 33 0
Trimethoprim, TMP R 100 0 31 0
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Appendix 8a - Deviations from expected results in the enterococci trial
Obtained Obtained Expected Expected
interpretation value interpretation Mic
LAB. 001 EURL ENT 6.3 Chloramphenicol, CHL S 32 R 64 1 MIC
LAB. 011 EURL ENT 6.5 Streptomycin, STR S 512 R 2048 1 MIC
LAB. 016 EURL ENT 6.1 Erythromycin, ERY R 8 S 2 1 MIC
EURL ENT 6.1 Erythromycin, ERY R 8 S 2 1
EURL ENT 6.3 Chloramphenicol, CHL S 32 R 64 1
LAB. 020 EURL ENT 6.2 Ampicillin , AMP R 8 S 4 1
EURL ENT 6.5 Streptomycin, STR S 512 R 2048 1
LAB. 021 EURL ENT 6.5 Streptomycin, STR S R 2048 1 MIC
LAB. 022 EURL ENT 6.2 Ampicillin , AMP R 8 S 4 1 MIC
LAB. 025 EURL ENT 6.1 Erythromycin, ERY R 8 S 2 1
EURL ENT 6.2 Ampicillin , AMP R 8 S 4 1
LAB. 026 EURL ENT 6.3 Streptomycin, STR S 10 R >2048 1
EURL ENT 6.5 Streptomycin, STR S 10 R 2048 1
LAB. 029 EURL ENT 6.3 Vancomycin, VAN R 128 S <=1 1
EURL ENT 6.4 Vancomycin, VAN R 128 S 4 1
LAB. 033 EURL ENT 6.7 Tetracycline, TET S >64 R >32 1 MIC
LAB. 034 EURL ENT 6.1 Erythromycin, ERY R >8 S 2 1
EURL ENT 6.2 Erythromycin, ERY R 8 S 1 1
EURL ENT 6.6 Streptomycin, STR S 128 R >2048 1
EURL ENT 6.8 Streptomycin, STR R 1024 S 128 1
LAB. 036 EURL ENT 6.1 Erythromycin, ERY R 16 S 2 1 MIC
LAB. 037 EURL ENT 6.3 Chloramphenicol, CHL S 32 R 64 1
EURL ENT 6.5 Streptomycin, STR S 512 R 2048 1
LAB. 039 EURL ENT 6.3 Chloramphenicol, CHL S 32 R 64 1 MIC
LAB. 040 EURL ENT 6.1 Quinu-dalfo-pristin, Q-D R 8 S 4 1
EURL ENT 6.1 Streptomycin, STR R 512 S <=64 1
EURL ENT 6.2 Streptomycin, STR R 512 S <=64 1
EURL ENT 6.4 Gentamicin, GEN R 128 S <=16 1
EURL ENT 6.4 Streptomycin, STR R 512 S 128 1
EURL ENT 6.5 Gentamicin, GEN R 128 S <=16 1
EURL ENT 6.7 Gentamicin, GEN R 128 S <=16 1
EURL ENT 6.7 Streptomycin, STR R 1024 S 128 1
EURL ENT 6.8 Gentamicin, GEN R 128 S <=16 1
EURL ENT 6.8 Streptomycin, STR R 1024 S 128 1
LAB. 041 EURL ENT 6.2 Streptomycin, STR R >128 S <=64 1
EURL ENT 6.3 Chloramphenicol, CHL S 32 R 64 1
LAB. 046 EURL ENT 6.1 Erythromycin, ERY R 8 S 2 1 MIC
Lab no. Strain Antimicrobial Count
LAB. 017
Method
MIC
MIC
MIC
DD
MIC
MIC
MIC
MIC
MIC
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Obtained Obtained Expected Expected
interpretation value interpretation Mic
Lab no. Strain Antimicrobial Count Method
LAB. 054 EURL ENT 6.1 Ampicillin , AMP R 14 S <=2 1
EURL ENT 6.1 Ciprofloxacin , CIP R 12 S <=0.5 1
EURL ENT 6.1 Erythromycin, ERY R 8 S 2 1
EURL ENT 6.1 Gentamicin, GEN R 0 S <=16 1
EURL ENT 6.1 Linezolid, LZD R 18 S 2 1
EURL ENT 6.1 Streptomycin, STR R 0 S <=64 1
EURL ENT 6.1 Tetracycline, TET R 13 S <=1 1
EURL ENT 6.1 Vancomycin, VAN R 13 S <=1 1
EURL ENT 6.2 Ampicillin , AMP R 14 S 4 1
EURL ENT 6.2 Chloramphenicol, CHL R 12 S 4 1
EURL ENT 6.2 Ciprofloxacin , CIP R 10 S <=0.5 1
EURL ENT 6.2 Erythromycin, ERY R 9 S 1 1
EURL ENT 6.2 Gentamicin, GEN R 9 S <=16 1
EURL ENT 6.2 Linezolid, LZD R 16 S 2 1
EURL ENT 6.2 Streptomycin, STR R 0 S <=64 1
EURL ENT 6.3 Ampicillin , AMP R 13 S <=2 1
EURL ENT 6.3 Ciprofloxacin , CIP R 12 S 1 1
EURL ENT 6.3 Linezolid, LZD R 19 S 2 1
EURL ENT 6.3 Vancomycin, VAN R 11 S <=1 1
EURL ENT 6.4 Ampicillin , AMP R 16 S <=2 1
EURL ENT 6.4 Chloramphenicol, CHL R 0 S 8 1
EURL ENT 6.4 Ciprofloxacin , CIP R 9 S 1 1
EURL ENT 6.4 Erythromycin, ERY R 8 S <=0.5 1
EURL ENT 6.4 Gentamicin, GEN R 0 S <=16 1
EURL ENT 6.4 Linezolid, LZD R 17 S 2 1
EURL ENT 6.4 Streptomycin, STR R 0 S 128 1
EURL ENT 6.4 Tetracycline, TET R 12 S <=1 1
EURL ENT 6.4 Vancomycin, VAN R 10 S 4 1
EURL ENT 6.5 Ciprofloxacin , CIP R 0 S 1 1
EURL ENT 6.5 Erythromycin, ERY R 12 S <=0.5 1
EURL ENT 6.5 Gentamicin, GEN R 0 S <=16 1
EURL ENT 6.5 Linezolid, LZD R 19 S 2 1
EURL ENT 6.5 Vancomycin, VAN R 12 S <=1 1
EURL ENT 6.6 Ampicillin , AMP R 14 S <=2 1
EURL ENT 6.6 Chloramphenicol, CHL R 12 S 8 1
EURL ENT 6.6 Ciprofloxacin , CIP R 10 S 1 1
EURL ENT 6.6 Gentamicin, GEN R 0 S <=16 1
EURL ENT 6.6 Linezolid, LZD R 20 S 1 1
EURL ENT 6.6 Vancomycin, VAN R 9 S <=1 1
EURL ENT 6.7 Chloramphenicol, CHL R 0 S 8 1
EURL ENT 6.7 Ciprofloxacin , CIP R 10 S 1 1
EURL ENT 6.7 Erythromycin, ERY R 12 S <=0.5 1
EURL ENT 6.7 Gentamicin, GEN R 0 S <=16 1
EURL ENT 6.7 Linezolid, LZD R 20 S 2 1
EURL ENT 6.7 Streptomycin, STR R 0 S 128 1
EURL ENT 6.7 Vancomycin, VAN R 10 S <=1 1
EURL ENT 6.8 Chloramphenicol, CHL R 0 S 8 1
EURL ENT 6.8 Ciprofloxacin , CIP R 12 S 1 1
EURL ENT 6.8 Gentamicin, GEN R 0 S <=16 1
EURL ENT 6.8 Linezolid, LZD R 19 S 2 1
EURL ENT 6.8 Streptomycin, STR R 0 S 128 1
EURL ENT 6.8 Vancomycin, VAN R 11 S <=1 1
LAB. 057 EURL ENT 6.4 Streptomycin, STR R 9 S 128 1
EURL ENT 6.7 Streptomycin, STR R 10 S 128 1
EURL ENT 6.8 Streptomycin, STR R 11 S 128 1
LAB. 058 EURL ENT 6.5 Ampicillin , AMP R >8 S <=2 1 MIC
DD
DD
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Appendix 8b - Deviations from expected results in the staphylococci trial
Obtained Obtained Expected Expected
interpretat
ion
value
interpretat
ion
Mic
LAB. 004 EURL ST 6.6 Cefoxitin, FOX S 26.95 R 16 1 MIC
EURL ST 6.3 Trimethoprim, TMP R <=4 S 1 1
EURL ST 6.7 Erythromycin, ERY R >8 S 0.5 1
EURL ST 6.7 Streptomycin, STR R <=32 S <=4 1
EURL ST 6.4 Tetracycline, TET S 30 R 16 1
EURL ST 6.8 Sulfamethoxazole, SMX S 16 R 256 1
EURL ST 6.2 Trimethoprim, TMP R 4 S 2 1
EURL ST 6.3 Trimethoprim, TMP R 4 S 1 1
LAB. 018 EURL ST 6.8 Sulfamethoxazole, SMX S 14 R 256 1 DD
EURL ST 6.2 Sulfamethoxazole, SMX R >512 S 64 1
EURL ST 6.2 Trimethoprim, TMP R 4 S 2 1
EURL ST 6.3 Sulfamethoxazole, SMX R >512 S <=32 1
EURL ST 6.3 Trimethoprim, TMP R 4 S 1 1
EURL ST 6.5 Sulfamethoxazole, SMX R 512 S <=32 1
EURL ST 6.7 Trimethoprim, TMP R 4 S 1 1
LAB. 026 EURL ST 6.6 Tetracycline, TET S >32 R >32 1 MIC
EURL ST 6.2 Streptomycin, STR R 32 S <=4 1
EURL ST 6.2 Trimethoprim, TMP R 4 S 2 1
EURL ST 6.2 Trimethoprim, TMP R 4 S 2 1
EURL ST 6.3 Trimethoprim, TMP R 4 S 1 1
LAB. 039 EURL ST 6.2 Trimethoprim, TMP R 4 S 2 1 MIC
EURL ST 6.1 Streptomycin, STR R 32 S 8 1
EURL ST 6.1 Sulfamethoxazole, SMX R 256 S <=32 1
EURL ST 6.6 Erythromycin, ERY R 4 S 0.5 1
EURL ST 6.7 Streptomycin, STR R 32 S <=4 1
EURL ST 6.2 Sulfamethoxazole, SMX R >512 S 64 1
EURL ST 6.5 Sulfamethoxazole, SMX R 512 S <=32 1
EURL ST 6.1 Gentamicin, GEN R 11 S <=0.25 1
EURL ST 6.1 Streptomycin, STR R 9 S 8 1
EURL ST 6.2 Gentamicin, GEN R 9 S <=0.25 1
EURL ST 6.2 Streptomycin, STR R 8 S <=4 1
EURL ST 6.3 Ciprofloxacin, CIP R 14 S 0.5 1
EURL ST 6.3 Gentamicin, GEN R 10 S 0.5 1
EURL ST 6.3 Streptomycin, STR R 8 S 8 1
EURL ST 6.4 Gentamicin, GEN R 10 S <=0.25 1
EURL ST 6.4 Streptomycin, STR R 9 S 8 1
EURL ST 6.5 Gentamicin, GEN R 10 S 0.5 1
EURL ST 6.7 Gentamicin, GEN R 12 S 0.5 1
EURL ST 6.7 Streptomycin, STR R 0 S <=4 1
EURL ST 6.2 Sulfamethoxazole, SMX R 6 S 64 1
EURL ST 6.3 Sulfamethoxazole, SMX R 6 S <=32 1
EURL ST 6.6 Penicillin, PEN S 13 R 8 1
EURL ST 6.8 Gentamicin, GEN S 13 R >16 1
EURL ST 6.8 Sulfamethoxazole, SMX S 15 R 256 1
EURL ST 6.2 Streptomycin, STR R 32 S <=4 1
EURL ST 6.2 Sulfamethoxazole, SMX R 512 S 64 1
EURL ST 6.2 Trimethoprim, TMP R 4 S 2 1
EURL ST 6.3 Sulfamethoxazole, SMX R 512 S <=32 1
EURL ST 6.5 Tetracycline, TET S 1 R 32 1
LAB. 057
LAB. 058
MIC
MIC
DD
MIC
LAB. 017
LAB. 006
LAB. 013
LAB. 020
LAB. 034
LAB. 036
LAB. 040
LAB. 042
DD
DD
MIC
LAB. 054
LAB. 056
MIC
DD
MIC
MIC
MIC
Lab no. Strain Antimicrobial Count Method
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Appendix 8c- Deviations from expected results in the E. coli  trial 
Obtained Obtained Expected Expected
interpreta
tion
value
interpretat
ion
Mic
LAB. 004 EURL EC 6.1 Streptomycin, STR R 16 S <=8 1 MIC
LAB. 019 EURL EC 6.2 Ciprofloxacin, CIP S 0.5 R 0.25 1 MIC
LAB. 020 EURL EC 6.2 Sulfamethoxazole, SMX R 128 S <=64 1 MIC
LAB. 026 EURL EC 6.7 Ceftazidime, CAZ S 0.5 R 1 1 MIC
EURL EC 6.1 Ceftiofur, XNL S 20mm R 8 1
EURL EC 6.2 Ampicillin, AMP R 32 S 4 1
EURL EC 6.8 Ceftiofur, XNL S 20mm R 8 1
LAB. 032 EURL EC 6.7 Ceftazidime, CAZ S <=0.5 R 1 1 MIC
LAB. 033 EURL EC 6.1 Streptomycin, STR R 16 S <=8 1 MIC
EURL EC 6.1 Streptomycin, STR R 16 S <=8 1
EURL EC 6.1 Sulfamethoxazole, SMX R >1024 S <=64 1
EURL EC 6.2 Ampicillin, AMP R 32 S 4 1
EURL EC 6.2 Cefotaxime, CTX R 0.5 S <=0.12 1
EURL EC 6.2 Ceftazidime, CAZ R 4 S 0.125 1
EURL EC 6.2 Streptomycin, STR R 16 S <=8 1
EURL EC 6.2 Sulfamethoxazole, SMX R >1024 S <=64 1
EURL EC 6.3 Cefotaxime, CTX R 2 S <=0.12 1
EURL EC 6.3 Ceftazidime, CAZ R 16 S 0.125 1
EURL EC 6.3 Ciprofloxacin, CIP R 0.12 S <=0.015 1
EURL EC 6.5 Ceftazidime, CAZ R 2 S 0.06 1
EURL EC 6.6 Ceftazidime, CAZ R 8 S 0.25 1
EURL EC 6.6 Sulfamethoxazole, SMX R >1024 S <=64 1
EURL EC 6.8 Sulfamethoxazole, SMX R 1024 S <=64 1
EURL EC 6.6 Streptomycin, STR R 32 S <=8 1
EURL EC 6.7 Ceftazidime, CAZ S 0.5 R 1 1
EURL EC 6.8 Ciprofloxacin, CIP R 0.12 S 0.03 1
EURL EC 6.8 Streptomycin, STR R 32 S <=8 1
EURL EC 6.1 Gentamicin, GEN R 12 S 1 1
EURL EC 6.1 Streptomycin, STR R 9 S <=8 1
EURL EC 6.1 Tetracycline, TET R 14 S <=2 1
EURL EC 6.2 Ampicillin, AMP R 12 S 4 1
EURL EC 6.2 Gentamicin, GEN R 12 S 1 1
EURL EC 6.2 Streptomycin, STR R 8 S <=8 1
EURL EC 6.3 Gentamicin, GEN R 12 S <=0.5 1
EURL EC 6.4 Streptomycin, STR R 10 S <=8 1
EURL EC 6.5 Gentamicin, GEN R 12 S 1 1
EURL EC 6.6 Ampicillin, AMP R 12 S 4 1
EURL EC 6.6 Gentamicin, GEN R 11 S <=0.5 1
EURL EC 6.6 Streptomycin, STR R 10 S <=8 1
EURL EC 6.6 Tetracycline, TET R 14 S <=2 1
EURL EC 6.8 Gentamicin, GEN R 12 S 1 1
EURL EC 6.8 Streptomycin, STR R 11 S <=8 1
EURL EC 6.2 Ciprofloxacin, CIP S 29 R 0.25 1
EURL EC 6.4 Ceftazidime, CAZ S 24 R 2 1
EURL EC 6.5 Streptomycin, STR S 13 R >128 1
EURL EC 6.7 Ceftazidime, CAZ S 25 R 1 1
EURL EC 6.7 Gentamicin, GEN S 14 R >16 1
EURL EC 6.8 Cefotaxime, CTX S 19 R >4 1
LAB. 058 EURL EC 6.8 Streptomycin, STR R 16 S <=8 1 MIC
LAB. 057
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